Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
21 Oct 2019 7:00 am
RNS
Farxiga approved in the US to reduce the risk of
17 Oct 2019 7:00 am
RNS
Trastuzumab deruxtecan granted FDA Priority Review
04 Oct 2019 3:04 pm
RNS
Holding(s) in Company
  3:00 pm
RNS
Holding(s) in Company
  7:00 am
RNS
Fasenra approved in the US for self-administration
03 Oct 2019 4:00 pm
RNS
Director Declaration
01 Oct 2019 3:00 pm
RNS
Total Voting Rights
  7:05 am
RNS
AstraZeneca divests rights for Losec to Cheplaphar
  7:00 am
RNS
Update on US regulatory review of PT010 in COPD
30 Sep 2019 3:30 pm
RNS
Lynparza more than doubled the time without
  7:00 am
RNS
Tagrisso is the only 1st-line treatment for EGFR-
  7:00 am
RNS
Lynparza improved the time women lived without
23 Sep 2019 7:00 am
RNS
Qtrilmet recommended for approval in EU by CHMP
18 Sep 2019 7:00 am
RNS
AstraZeneca amends collaboration with Ironwood
09 Sep 2019 8:38 am
RNS
Imfinzi is first immunotherapy to show both
04 Sep 2019 7:11 am
RNS
Tagrisso approved in China as a 1st-line treatment
02 Sep 2019 3:00 pm
RNS
Total Voting Rights
  7:05 am
RNS
Brilinta reduced the risk of cardiovascular events
  7:00 am
RNS
Detailed results from Phase III DAPA-HF trial
29 Aug 2019 7:00 am
RNS
Anifrolumab Phase III trial meets primary endpoint
28 Aug 2019 7:05 am
RNS
Fasenra granted US Orphan Drug Designation for
  7:00 am
RNS
Breztri Aerosphere Phase III ETHOS trial met
22 Aug 2019 7:00 am
RNS
Roxadustat approved in China for the treatment of
  7:00 am
RNS
AstraZeneca agrees to buy US FDA Priority Review
21 Aug 2019 7:00 am
RNS
Update on the Phase III NEPTUNE trial
20 Aug 2019 7:00 am
RNS
Farxiga met primary endpoint in landmark Phase III
19 Aug 2019 7:00 am
RNS
Directorate Change
14 Aug 2019 7:00 am
RNS
Lynparza Phase III PAOLA-1 trial met primary endpo
  7:00 am
RNS
Calquence granted US Breakthrough Therapy Designat
09 Aug 2019 9:28 am
RNS
Amendment: Tagrisso significantly improves overall
  7:00 am
RNS
Tagrisso significantly improves overall survival
07 Aug 2019 7:00 am
RNS
Lynparza Phase III PROfound trial in HRR*
05 Aug 2019 7:00 am
RNS
Forxiga label updated in the EU in type-2 diabetes
01 Aug 2019 3:00 pm
RNS
Total Voting Rights
25 Jul 2019 7:00 am
RNS
AZN: H1 2019 Results
15 Jul 2019 7:00 am
RNS
Update on US regulatory decision for Farxiga
12 Jul 2019 7:00 am
RNS
Imfinzi granted US Orphan Drug Designation for
01 Jul 2019 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Forxiga receives positive EU CHMP opinion for
  7:00 am
RNS
Fasenra receives positive EU CHMP opinion for self
27 Jun 2019 7:00 am
RNS
Imfinzi improves overall survival at interim
19 Jun 2019 7:00 am
RNS
Breztri Aerosphere (PT010) approved in Japan for
  7:00 am
RNS
Lynparza approved in Japan for 1st-line
  7:00 am
RNS
Bevespi Aerosphere approved by the Japanese
18 Jun 2019 7:00 am
RNS
Lynparza approved in the EU for 1st-line
17 Jun 2019 7:00 am
RNS
Calquence significantly prolonged the time patient
12 Jun 2019 4:45 pm
RNS
Publication of a Prospectus
06 Jun 2019 7:00 am
RNS
Calquence Phase III ELEVATE-TN trial met primary
05 Jun 2019 12:36 pm
EQS
AstraZeneca: Where has all the cash gone?
03 Jun 2019 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Lynparza nearly doubled time patients lived with
10 May 2019 7:00 am
RNS
Pooled analyses of the roxadustat global Phase III
08 May 2019 2:00 pm
RNS
Director/PDMR Shareholding
  11:00 am
RNS
Director Declaration
  7:00 am
RNS
Trastuzumab deruxtecan demonstrated clinically
07 May 2019 7:00 am
RNS
Calquence PhIII ASCEND trial met primary endpoint
03 May 2019 7:00 am
RNS
Qternmet XR approved in the US for type-2 diabetes
01 May 2019 3:00 pm
RNS
Total Voting Rights
  12:00 pm
RNS
Director/PDMR Shareholding
29 Apr 2019 7:00 am
RNS
Lynparza receives positive EU CHMP opinion for 1st
26 Apr 2019 5:45 pm
RNS
Result of AGM
  7:00 am
RNS
AZN: Q1 2019 Results
10 Apr 2019 7:00 am
RNS
Lynparza approved in EU for the treatment of germl
09 Apr 2019 4:10 pm
EQS
Global Pharmaceuticals: 2018 industry sales
04 Apr 2019 1:30 pm
RNS
Holding(s) in Company
03 Apr 2019 10:00 am
RNS
Director/PDMR Shareholding
02 Apr 2019 3:00 pm
RNS
Total Voting Rights
01 Apr 2019 6:00 pm
RNS
Astrazeneca
  3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Selumetinib gets Breakthrough Therapy Designation
29 Mar 2019 5:15 pm
RNS
Results of Placing
  7:00 am
RNS
Proposed placing of new ordinary shares
  7:00 am
RNS
AZ and Daiichi Sankyo enter collaboration in novel
27 Mar 2019 7:00 am
RNS
Forxiga approved in Japan for type-1 diabetes
25 Mar 2019 7:00 am
RNS
Forxiga approved in Europe for type-1 diabetes
18 Mar 2019 7:00 am
RNS
US FDA grants saracatinib ODD for IPF
14 Mar 2019 12:00 pm
RNS
Notice of AGM
12 Mar 2019 12:00 pm
RNS
Director/PDMR Shareholding
06 Mar 2019 7:00 am
RNS
Filing of Form 20-F with SEC
05 Mar 2019 11:00 am
RNS
Annual Financial Report
04 Mar 2019 4:04 pm
RNS
Holding(s) in Company
01 Mar 2019 3:00 pm
RNS
Total Voting Rights
  1:45 pm
RNS
Lynparza receives positive EU CHMP opinion
26 Feb 2019 7:00 am
RNS
Lynparza significantly delayed disease progression
25 Feb 2019 7:00 am
RNS
Brilinta's PhIII THEMIS trial met primary endpoint
14 Feb 2019 7:00 am
RNS
AstraZeneca Full-Year and Q4 2018 Results
06 Feb 2019 7:00 am
RNS
US FDA grants Fasenra Orphan Drug Designation
05 Feb 2019 7:05 am
RNS
US FDA grants Breakthrough Therapy Designation
  7:00 am
RNS
EMA grants PRIME eligibility for MEDI8897
01 Feb 2019 3:00 pm
RNS
Total Voting Rights
  1:17 pm
RNS
Forxiga receives positive EU CHMP opinion
25 Jan 2019 2:00 pm
RNS
Completion of divestment of US Synagis rights
07 Jan 2019 1:00 pm
RNS
AstraZeneca announces organisational changes
02 Jan 2019 3:00 pm
RNS
Total Voting Rights
20 Dec 2018 1:47 pm
RNS
Bevespi Aerosphere approved in the EU for COPD
  7:05 am
RNS
Lynparza meets primary endpoint in SOLO-3 trial
  7:00 am
RNS
Phase III ROCKIES and OLYMPUS roxadustat trials
19 Dec 2018 6:31 pm
RNS
FDA approves Lynparza as 1L maintenance therapy
18 Dec 2018 9:09 am
RNS
Roxadustat approved in China for the treatment of
14 Dec 2018 7:00 am
RNS
Directorate Change
07 Dec 2018 7:00 am
RNS
Update on the Phase III EAGLE trial of Imfinzi
06 Dec 2018 7:00 am
RNS
Divestment of rights to Covis completed
04 Dec 2018 3:00 pm
RNS
Director/PDMR Shareholding
03 Dec 2018 4:00 pm
RNS
Block listing Interim Review
  4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Gr?nenthal Agreement for Nexium, Vimovo Completed
26 Nov 2018 7:00 am
RNS
US FDA grants Fasenra ODD for EGPA
16 Nov 2018 7:00 am
RNS
AstraZeneca provides update on Phase III MYSTIC
13 Nov 2018 7:00 am
RNS
AstraZeneca to divest US Synagis rights to Sobi
12 Nov 2018 7:05 am
RNS
US FDA accepts regulatory submission for Lynparza
  7:00 am
RNS
Farxiga significantly reduced hospitalisation for
08 Nov 2018 7:00 am
RNS
AZN: Year-to-Date and Q3 2018 Results
06 Nov 2018 7:00 am
RNS
Divestment of rights to Covis Pharma
01 Nov 2018 3:00 pm
RNS
Total Voting Rights
31 Oct 2018 9:45 am
RNS
Additional financial information-Gr?nenthal deal
30 Oct 2018 7:00 am
RNS
Gr?nenthal Agreement for rights to Nexium, Vimovo
23 Oct 2018 7:00 am
RNS
AstraZeneca Extends Innate Pharma Collaboration
22 Oct 2018 7:00 am
RNS
Lynparza shows 70% reduction in PFS ovarian cancer
19 Oct 2018 1:09 pm
RNS
CHMP positive opinion Bevespi Aerosphere
16 Oct 2018 7:00 am
RNS
FDA Orphan Drug for Lynparza in pancreatic cancer
01 Oct 2018 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Atacand Agreement with Cheplapharm Completed
28 Sep 2018 4:00 pm
RNS
Previous Announcement Regarding Appointment Of NED
25 Sep 2018 1:15 pm
RNS
Overall survival data for Imfinzi: Stage III NSCLC
24 Sep 2018 4:10 pm
RNS
EMA approves AZ's Imfinzi for Stage III NSCLC
  7:00 am
RNS
Farxiga gets positive result in DECLARE-TIMI 58
14 Sep 2018 7:00 am
RNS
FDA approves AZ's Lumoxiti in hairy cell leukaemia
07 Sep 2018 7:00 am
RNS
Tezepelumab FDA Breakthrough Therapy Designation
06 Sep 2018 7:00 am
RNS
Directorate Change
03 Sep 2018 3:00 pm
RNS
Total Voting Rights
31 Aug 2018 7:00 am
RNS
AstraZeneca Update on Anifrolumab in SLE
30 Aug 2018 7:00 am
RNS
EC approves Bydureon BCise device for T2 diabetes
23 Aug 2018 7:00 am
RNS
AstraZeneca PIIIb trial update for Bevespi in COPD
21 Aug 2018 7:00 am
RNS
AZ's Tagrisso approved in Japan for 1st-line NSCLC
15 Aug 2018 7:00 am
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2018 7:00 am
RNS
EMA grants OD for selumetinib in NF1
01 Aug 2018 3:00 pm
RNS
Total Voting Rights
27 Jul 2018 2:00 pm
RNS
CHMP recommends Imfinzi for Stage III nsclc
26 Jul 2018 7:00 am
RNS
AZN: H1 2018 Results
24 Jul 2018 7:00 am
RNS
Atacand to be divested to Cheplapharm in Europe
18 Jul 2018 4:11 pm
RNS
Holding(s) in Company
  12:00 pm
RNS
Holding(s) in Company
02 Jul 2018 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Lynparza approved in Japan for BRCAm breast cancer
  7:00 am
RNS
Imfinzi approved in Japan for Stage III nsclc
29 Jun 2018 3:00 pm
RNS
Bydureon receives positive CHMP opinion for BCise
28 Jun 2018 1:30 pm
RNS
AZ and Luye Pharma complete agreement for Seroquel
27 Jun 2018 7:00 am
RNS
Lynparza: significant PFS 1st-line ovarian cancer
26 Jun 2018 7:00 am
RNS
Board Committee Changes
22 Jun 2018 7:00 am
RNS
Publication of a Prospectus
12 Jun 2018 7:00 am
RNS
Update: lanabecestat Phase III Alzheimer's trials
08 Jun 2018 5:30 pm
RNS
EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
  7:00 am
RNS
Director Declaration
01 Jun 2018 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
  11:00 am
RNS
Director Declaration
30 May 2018 7:00 am
RNS
Update on TERRANOVA PIII trial for Fasenra in COPD
25 May 2018 7:00 am
RNS
AZ's Imfinzi: significant OS in Stage III nsclc
21 May 2018 7:00 am
RNS
AZ regulatory submission in Japan for Forxiga
  7:00 am
RNS
US FDA approves Lokelma for adult hyperkalaemia
18 May 2018 5:30 pm
RNS
Result of AGM
  7:00 am
RNS
AZN: Q1 2018 Results
11 May 2018 7:00 am
RNS
AstraZeneca update on Fasenra PIII trial in COPD
08 May 2018 11:00 am
RNS
EMA approves Lynparza: maintenance ovarian cancer
  7:00 am
RNS
AZ and Luye Pharma enter agreement for Seroquel
04 May 2018 12:00 pm
RNS
Director Declaration
01 May 2018 3:00 pm
RNS
Total Voting Rights
27 Apr 2018 12:30 pm
RNS
AZ: positive CHMP for Tagrisso first-line nsclc
24 Apr 2018 7:00 am
RNS
Issue of Equity - AstraZeneca
  7:00 am
RNS
AstraZeneca:high level results of the ARCTIC trial
19 Apr 2018 7:00 am
RNS
FDA approves Tagrisso for 1st-line use in NSCLC
13 Apr 2018 11:00 am
RNS
Notice of AGM
05 Apr 2018 7:00 am
RNS
Directorate Change
03 Apr 2018 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA
  7:00 am
RNS
AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU
28 Mar 2018 3:00 pm
RNS
Director/PDMR Shareholding
26 Mar 2018 3:00 pm
RNS
Director/PDMR Shareholding
22 Mar 2018 4:48 pm
RNS
Lokelma approved in the EU
12 Mar 2018 7:00 am
RNS
ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE
07 Mar 2018 7:00 am
RNS
Filing of Form 20-F with SEC
06 Mar 2018 11:00 am
RNS
Annual Financial Report
01 Mar 2018 3:00 pm
RNS
Total Voting Rights
23 Feb 2018 12:35 pm
RNS
Lynparza CHMP for ovarian cancer maintainance
19 Feb 2018 7:00 am
RNS
AstraZeneca's IMFINZI approved for Stage III nsclc
15 Feb 2018 7:00 am
RNS
Selumetinib in NF1 gets FDA orphan drug status
05 Feb 2018 2:00 pm
RNS
Director/PDMR Shareholding
02 Feb 2018 7:00 am
RNS
AZN: Full-Year 2017 Results
01 Feb 2018 3:00 pm
RNS
Total Voting Rights
26 Jan 2018 6:20 pm
RNS
AZ Reports Phase III Results for PT010 in COPD
19 Jan 2018 7:00 am
RNS
ASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPAN
  7:00 am
RNS
LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER
12 Jan 2018 4:10 pm
RNS
FDA approves Lynparza for metastatic breast cancer
10 Jan 2018 3:10 pm
RNS
AstraZeneca's Fasenra approved in the EU
02 Jan 2018 3:00 pm
RNS
Total Voting Rights
28 Dec 2017 2:00 pm
RNS
Director/PDMR Shareholding
18 Dec 2017 7:00 am
RNS
FDA accepts Tagrisso submission for 1st-line nsclc
15 Dec 2017 12:00 pm
RNS
Director/PDMR Shareholding
01 Dec 2017 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
28 Nov 2017 7:00 am
RNS
EMA accepts Tagrisso submission for 1st-line nsclc
27 Nov 2017 7:00 am
RNS
AZ submits Tagrisso in Japan for 1st-line nsclc
15 Nov 2017 7:00 am
RNS
AZ Fasenra receives FDA approval for severe asthma
10 Nov 2017 11:35 am
RNS
BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA
09 Nov 2017 7:00 am
RNS
AZN: Year-To-Date and Q3 2017 Results Announcement
01 Nov 2017 3:00 pm
RNS
Total Voting Rights
  7:03 am
RNS
ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL
  7:00 am
RNS
AstraZeneca tralokinumab update in severe asthma
31 Oct 2017 5:05 pm
RNS
US FDA approves AstraZeneca's Calquence for MCL
23 Oct 2017 7:05 am
RNS
AZ and MSD rapidly advance Lynparza in Japan
  7:00 am
RNS
US FDA approves Bydureon BCise for type-2 diabetes
18 Oct 2017 7:00 am
RNS
FDA Priority Review for Lynparza in breast cancer
17 Oct 2017 7:00 am
RNS
FDA accepts sBLA file for Imfinzi; priority review
09 Oct 2017 7:00 am
RNS
FDA grants Tagrisso BTD for 1st-line EGFR nsclc
02 Oct 2017 3:00 pm
RNS
Total Voting Rights
26 Sep 2017 12:00 pm
RNS
Director/PDMR Shareholding
14 Sep 2017 7:00 am
RNS
Aspen acquires remaining rights to AZ anaesthetics
11 Sep 2017 7:00 am
RNS
IMFINZI superior PFS in Stage III lung cancer
  7:00 am
RNS
Tagrisso potential standard of care in lung cancer
07 Sep 2017 12:39 pm
RNS
Celgene and AZ update on Fusion trial programme
  7:00 am
RNS
AZ Duaklir improves lung function in COPD patients
  7:00 am
RNS
AZ tezepelumab cuts exacerbations in severe asthma
05 Sep 2017 7:00 am
RNS
Directorate Change
01 Sep 2017 3:00 pm
RNS
Total Voting Rights
29 Aug 2017 7:00 am
RNS
Faslodex gets US FDA OK for expanded use in breast
18 Aug 2017 7:00 am
RNS
Lynparza gets broad FDA approval in ovarian cancer
16 Aug 2017 7:00 am
RNS
Directorate Change
14 Aug 2017 4:30 pm
RNS
Holding(s) in Company
10 Aug 2017 1:30 pm
RNS
Publication of a Prospectus
02 Aug 2017 7:00 am
RNS
AZ acalabrutinib submission accepted by US FDA
01 Aug 2017 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
BTD for AZ's acalabrutinib in mantle cell lymphoma
31 Jul 2017 7:00 am
RNS
Imfinzi granted BTD by US FDA for Stage III nsclc
28 Jul 2017 11:00 am
RNS
Director/PDMR Shareholding
27 Jul 2017 7:15 am
RNS
Tagrisso significantly improves FLAURA
  7:11 am
RNS
AZ reports initial results from MYSTIC lung trial
  7:06 am
RNS
AZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL
  7:00 am
RNS
AstraZeneca PLC - H1 2017 Results
26 Jul 2017 4:46 pm
RNS
Faslodex receives EU approval for 1L breast cancer
21 Jul 2017 3:45 pm
RNS
Holding(s) in Company
03 Jul 2017 2:59 pm
RNS
Total Voting Rights
  7:00 am
RNS
AZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI
  7:00 am
RNS
AZ COMPLETES ZOMIG DIVESTMENT WITH GR?NENTHAL
23 Jun 2017 12:46 pm
RNS
Faslodex CHMP positive opinion in 1L breast cancer
07 Jun 2017 7:13 am
RNS
AZ agreement with Gr?nenthal for rights to Zomig
06 Jun 2017 7:00 am
RNS
ASTRAZENECA PRICES A $2BN BOND ISSUE
05 Jun 2017 7:00 am
RNS
LYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER
01 Jun 2017 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
31 May 2017 7:00 am
RNS
Directorate Change
24 May 2017 3:00 pm
RNS
Director/PDMR Shareholding
23 May 2017 7:00 am
RNS
Bydureon EXSCEL trial meets T2D safety objective
22 May 2017 7:00 am
RNS
AZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE
16 May 2017 3:00 pm
RNS
Director/PDMR Shareholding
12 May 2017 7:00 am
RNS
IMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCER
10 May 2017 7:00 am
RNS
AZ updates on tralokinumab trial in severe asthma
02 May 2017 2:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
DURVALUMAB RECEIVES US FDA ACCELERATED APPROVAL
27 Apr 2017 5:30 pm
RNS
Result of AGM
  7:00 am
RNS
AstraZeneca: Q1 2017 Results
25 Apr 2017 1:30 pm
RNS
TAGRISSO RECEIVES FULL APPROVAL IN THE EU
12 Apr 2017 5:34 pm
RNS
Notification of Major Interest in Shares
03 Apr 2017 3:00 pm
RNS
Total Voting Rights
31 Mar 2017 7:01 am
RNS
Tagrisso (osimertinib) receives FDA full approval
  7:00 am
RNS
AZ COMPLETES AGREEMENT WITH TERSERA THERAPEUTICS
28 Mar 2017 4:00 pm
RNS
Director/PDMR Shareholding
27 Mar 2017 3:00 pm
RNS
Director/PDMR Shareholding
17 Mar 2017 7:00 am
RNS
US FDA issues CRL for ZS-9 in hyperkalaemia
16 Mar 2017 11:00 am
RNS
Notice of AGM
15 Mar 2017 7:00 am
RNS
LYNPARZA PFS IN BRCA OVARIAN MAINTENANCE THERAPY
08 Mar 2017 7:00 am
RNS
Filing of Form 20-F with SEC
07 Mar 2017 2:30 pm
RNS
Annual Financial Report
06 Mar 2017 7:00 am
RNS
Directorate Change
03 Mar 2017 7:00 am
RNS
ALLIANCE WITH SANOFI PASTEUR FOR MEDI8897
01 Mar 2017 4:30 pm
RNS
Total Voting Rights
28 Feb 2017 7:02 am
RNS
FDA approves once-daily Qtern for type-2 diabetes
24 Feb 2017 12:32 pm
RNS
CHMP positive opinion for ZS-9 in hyperkalaemia
20 Feb 2017 7:00 am
RNS
AZ licenses Zoladex to TerSera for the US & Canada
17 Feb 2017 7:00 am
RNS
Lynparza positive in metastatic BRCA breast cancer
16 Feb 2017 12:01 pm
RNS
SILIQ (BRODALUMAB) APPROVED BY US FDA
02 Feb 2017 7:00 am
RNS
AZN: FY16 and Q4 2016 Results
01 Feb 2017 4:00 pm
RNS
Total Voting Rights
26 Jan 2017 10:00 am
RNS
SYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE US
17 Jan 2017 7:00 am
RNS
AZ 1st-line lung cancer immuno-oncology programme
03 Jan 2017 4:00 pm
RNS
Total Voting Rights
23 Dec 2016 7:00 am
RNS
AZ COMPLETES SALE OF ANTIBIOTICS BUSINESS
16 Dec 2016 1:00 pm
RNS
Director/PDMR Shareholding
09 Dec 2016 3:05 pm
RNS
FDA accepts durvalumab for BLA in bladder cancer
06 Dec 2016 9:30 am
RNS
Tagrisso data shows superiority over chemotherapy
05 Dec 2016 7:00 am
RNS
AZ completes agreement for Rhinocort Aqua rights
01 Dec 2016 4:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
22 Nov 2016 7:00 am
RNS
AZ head and neck cancer trials resume enrolment
17 Nov 2016 7:00 am
RNS
AZ out-licensing deal with Allergan completed
10 Nov 2016 7:04 am
RNS
Year-To-Date and Q3 2016 Results
09 Nov 2016 7:00 am
RNS
Directorate Change
01 Nov 2016 3:30 pm
RNS
Dealing by Person Closely Associated
  3:00 pm
RNS
Total Voting Rights
31 Oct 2016 1:47 pm
RNS
AZ completes US Aralez agreement for Toprol-XL
27 Oct 2016 4:51 pm
RNS
AstraZeneca Head and Neck Cancer Trials
26 Oct 2016 7:00 am
RNS
Positive results in AstraZeneca Lynparza trial
18 Oct 2016 7:00 am
RNS
FDA accepts for review ZS-9 NDA for hyperkalaemia
07 Oct 2016 7:00 am
RNS
AZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US
04 Oct 2016 7:05 am
RNS
AZ agreement with Aralez for Toprol-XL in US
  7:00 am
RNS
AstraZeneca reports top-line EUCLID results in PAD
03 Oct 2016 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
MedImmune out-licenses medicine to Allergan
28 Sep 2016 7:00 am
RNS
CHANGE TO ASTRAZENECA BOARD OF DIRECTORS
26 Sep 2016 4:00 pm
RNS
Director/PDMR Shareholding
22 Sep 2016 11:00 am
RNS
Director Declaration
01 Sep 2016 2:30 pm
RNS
Total Voting Rights
  7:00 am
RNS
AstraZeneca Completes Aspen Agreement
24 Aug 2016 7:00 am
RNS
AZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
18 Aug 2016 1:00 pm
RNS
Director Declaration
16 Aug 2016 7:00 am
RNS
AstraZeneca completes agreement with LEO Pharma
10 Aug 2016 2:41 pm
RNS
ASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
09 Aug 2016 7:00 am
RNS
ASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
01 Aug 2016 2:30 pm
RNS
Total Voting Rights
  11:00 am
RNS
Director/PDMR Shareholding
28 Jul 2016 7:00 am
RNS
AZN: H1 2016 Results
27 Jul 2016 9:00 am
RNS
Notice of Results
19 Jul 2016 2:15 pm
RNS
QTERN (saxa/dapa) EU approved for type-2 diabetes
18 Jul 2016 7:00 am
RNS
TAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIAL
14 Jul 2016 12:07 pm
RNS
Second Price Monitoring Extn
  12:02 pm
RNS
Price Monitoring Extension
13 Jul 2016 7:00 am
RNS
AZ resolves Faslodex patent litigation in the US
01 Jul 2016 5:30 pm
RNS
Total Voting Rights
  7:00 am
RNS
AZ enters licensing agreements with LEO Pharma
28 Jun 2016 7:00 am
RNS
Zavicefta approved in EU
23 Jun 2016 7:00 am
RNS
AstraZeneca updates on Flumist vaccine in the US
14 Jun 2016 3:00 pm
RNS
Director/PDMR Shareholding
09 Jun 2016 7:03 am
RNS
AZ agreement with Aspen for anaesthetics portfolio
03 Jun 2016 7:00 am
RNS
AZ completes US licensing agreement with Ironwood
02 Jun 2016 7:00 am
RNS
AZ LICENSES ZURAMPIC TO GR?NENTHAL GMBH
01 Jun 2016 12:00 pm
RNS
Block listing Interim Review
  11:30 am
RNS
Total Voting Rights
27 May 2016 12:36 pm
RNS
POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA
  7:03 am
RNS
Positive results from AstraZeneca Faslodex trial
  7:00 am
RNS
AstraZeneca receives CRL from US FDA for ZS-9
23 May 2016 4:00 pm
RNS
Director/PDMR Shareholding
18 May 2016 7:00 am
RNS
TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL
17 May 2016 7:00 am
RNS
POSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA
12 May 2016 7:00 am
RNS
SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US
11 May 2016 5:30 pm
RNS
Publication of Final Terms
09 May 2016 5:35 pm
RNS
Launch and pricing of EUR2.2bn bond issues
05 May 2016 3:00 pm
RNS
Publication of a Prospectus
03 May 2016 1:30 pm
RNS
Total Voting Rights
  7:01 am
RNS
AstraZeneca completes divestment of Imdur
  7:00 am
RNS
AZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY
29 Apr 2016 5:30 pm
RNS
Result of AGM
  12:46 pm
RNS
POSITIVE CHMP OPINION FOR CAZ AVI
  7:00 am
RNS
AZN: 1st Quarter Results
28 Apr 2016 9:00 am
RNS
Notice of Results
26 Apr 2016 9:29 am
RNS
AZ enters US licensing agreement with Ironwood
  7:01 am
RNS
BEVESPI AEROSPHERE APPROVED BY US FDA FOR COPD
08 Apr 2016 7:00 am
RNS
AZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIAL
01 Apr 2016 11:30 am
RNS
Total Voting Rights
29 Mar 2016 7:00 am
RNS
TAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTS
24 Mar 2016 3:00 pm
RNS
Director/PDMR Shareholding
23 Mar 2016 7:00 am
RNS
AZ reports results from Brilinta stroke trial
18 Mar 2016 10:30 am
RNS
Notice of AGM
08 Mar 2016 6:29 pm
RNS
Filing of Form 20-F with SEC
  12:00 pm
RNS
Annual Financial Report
01 Mar 2016 2:30 pm
RNS
Total Voting Rights
29 Feb 2016 1:45 pm
RNS
AZ REPORTS TOP-LINE RESULT OF TREMELIMUMAB TRIAL
  7:59 am
RNS
AZ enters licensing agreement with CMS for Plendil
26 Feb 2016 12:00 pm
RNS
Director/PDMR Shareholding
25 Feb 2016 8:57 am
RNS
ACALABRUTINIB ORPHAN DRUG DESIGNATION RECOMMENDED
19 Feb 2016 7:05 am
RNS
BRILIQUE APPROVED IN EU FOR HEART ATTACK PATIENTS
  7:00 am
RNS
ZURAMPIC APPROVED IN EU FOR GOUT PATIENTS
17 Feb 2016 7:00 am
RNS
Durvalumab granted BTD by FDA for cancer patients
16 Feb 2016 8:01 am
RNS
NEW EXTERNAL BOARD APPOINTMENT
04 Feb 2016 7:00 am
RNS
AstraZeneca Full-Year and Q4 2015 Results
03 Feb 2016 9:00 am
RNS
Notice of Results
  7:00 am
RNS
TAGRISSO approved in EU for cancer patients
02 Feb 2016 9:05 am
RNS
AZ Completes transaction with Acerta Pharma
01 Feb 2016 2:32 pm
RNS
Total Voting Rights
28 Jan 2016 7:00 am
RNS
Lynparza Granted BTD in US for Prostate Cancer
04 Jan 2016 2:00 pm
RNS
Director/PDMR Shareholding
  2:00 pm
RNS
Director/PDMR Shareholding
  1:30 pm
RNS
Total Voting Rights
23 Dec 2015 4:30 pm
RNS
Result of External Audit Tender
  7:00 am
RNS
LESINURAD APPROVED BY US FDA FOR GOUT
18 Dec 2015 12:41 pm
RNS
TAGRISSOT (OSIMERTINIB) POSITIVE CHMP OPINION
  12:41 pm
RNS
BRILIQUE (TICAGRELOR) POSITIVE EU CHMP OPINION
  12:40 pm
RNS
CHMP ISSUES POSITIVE OPINION ON LESINURAD FOR GOUT
  7:00 am
RNS
ATLANTIC TRIAL SUPPORTS CLINICAL ACTIVITY
17 Dec 2015 2:08 pm
RNS
ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA
  7:00 am
RNS
AZ INVESTS IN ACERTA PHARMA TO ENHANCE GROWTH
16 Dec 2015 7:12 am
RNS
AZ ACQUISITION OF TAKEDA'S RESPIRATORY BUSINESS
15 Dec 2015 3:06 pm
RNS
AZ COMPLETES AGREEMENT WITH PERRIGO
14 Dec 2015 7:56 am
RNS
Discussions with Acerta Pharma BV
02 Dec 2015 7:00 am
RNS
Late-Stage Pipeline Conference Call
01 Dec 2015 2:00 pm
RNS
Blocklisting Interim Review
  1:00 pm
RNS
Total Voting Rights
23 Nov 2015 7:00 am
RNS
AZ enters agreement w/ Perrigo for Entocort in US
13 Nov 2015 3:06 pm
RNS
AZD9291 Approved by the US FDA
11 Nov 2015 7:30 am
RNS
ASTRAZENECA PRICES A $6 BILLION BOND ISSUE
06 Nov 2015 7:00 am
RNS
AZ acquires ZS Pharma to strengthen CVMD portfolio
05 Nov 2015 7:02 am
RNS
3rd Quarter Results
04 Nov 2015 9:00 am
RNS
Notice of Results
02 Nov 2015 1:01 pm
RNS
Total Voting Rights
27 Oct 2015 5:50 pm
RNS
Director/PDMR Shareholding
26 Oct 2015 7:00 am
RNS
FDA AD COM RECOMMENDS THE APPROVAL OF LESINURAD
16 Oct 2015 7:00 am
RNS
Saxa/dapa FDC Complete Response Letter from FDA
07 Oct 2015 7:00 am
RNS
ASTRAZENECA COMPLETES DIVESTMENT OF CAPRELSA
01 Oct 2015 4:15 pm
RNS
Total Voting Rights - Replacement
  2:00 pm
RNS
Director/PDMR Shareholding
28 Sep 2015 2:30 pm
RNS
Director/PDMR Shareholding
  2:30 pm
RNS
Director/PDMR Shareholding
04 Sep 2015 7:00 am
RNS
US FDA APPROVES EXPANDED INDICATION FOR BRILINTA
01 Sep 2015 11:30 am
RNS
Total Voting Rights
  7:04 am
RNS
AstraZeneca and Valeant to partner on brodalumab
28 Aug 2015 4:00 pm
RNS
Director/PDMR Shareholding
24 Aug 2015 7:00 am
RNS
AstraZeneca appoints Dr Sean Bohen
03 Aug 2015 3:00 pm
RNS
Total Voting Rights
30 Jul 2015 7:01 am
RNS
Half Yearly Report
29 Jul 2015 9:00 am
RNS
Notice of Results
27 Jul 2015 11:00 am
RNS
Confirmation of Change in ADS Ratio
  7:00 am
RNS
AstraZeneca agreement with Genzyme on Caprelsa
22 Jul 2015 7:00 am
RNS
AstraZeneca commences Phase II Trial
17 Jul 2015 11:00 am
RNS
Holding(s) in Company
  7:05 am
RNS
AZ completes agreement with Tillotts for Entocort
14 Jul 2015 7:00 am
RNS
IRESSA approved by US FDA
09 Jul 2015 7:32 am
RNS
Agreement with Tillotts on Entocort
01 Jul 2015 11:00 am
RNS
Total Voting Rights
26 Jun 2015 12:00 pm
RNS
Change in ADS ratio
25 Jun 2015 11:30 am
RNS
Publication of Prospectus
16 Jun 2015 2:00 pm
RNS
Director/PDMR Shareholding
03 Jun 2015 3:00 pm
RNS
Holding(s) in Company
01 Jun 2015 3:00 pm
RNS
AstraZeneca PLC - Blocklisting Interim Review
  3:00 pm
RNS
Total Voting Rights
26 May 2015 7:01 am
RNS
UPDATE ON BRODALUMAB DEVELOPMENT PROGRAMME
13 May 2015 3:00 pm
RNS
Holding(s) in Company
08 May 2015 2:00 pm
RNS
Director/PDMR Shareholding
  11:00 am
RNS
Director/PDMR Shareholding - Replacement
07 May 2015 2:00 pm
RNS
Director Declaration
01 May 2015 4:00 pm
RNS
Director/PDMR Shareholding
  11:00 am
RNS
Total Voting Rights
29 Apr 2015 5:30 pm
RNS
Director/PDMR Shareholding
24 Apr 2015 5:30 pm
RNS
Result of AGM
  7:02 am
RNS
1st Quarter Results
  7:01 am
RNS
Collaboration with Celgene on PD-L1 in haematology
  7:00 am
RNS
AZ and Innate to collaborate in immuno-oncology
23 Apr 2015 9:00 am
RNS
Notice of Results
17 Apr 2015 7:00 am
RNS
Selumetinib granted Orphan Drug Designation by FDA
15 Apr 2015 7:02 am
RNS
Tremelimumab granted Orphan Drug Designation
  7:00 am
RNS
FDA REVIEWS SAVOR OUTCOMES STUDY RESULTS
01 Apr 2015 11:00 am
RNS
Total Voting Rights
30 Mar 2015 3:00 pm
RNS
Director/PDMR Shareholding
19 Mar 2015 11:00 am
RNS
Notice of AGM
  7:00 am
RNS
COLLABORATION WITH DAIICHI SANKYO INC
18 Mar 2015 7:04 am
RNS
POSITIVE PHASE III RESULTS FOR PT003 IN COPD
16 Mar 2015 7:00 am
RNS
BRILINTA PEGASUS-TIMI 54 STUDY
10 Mar 2015 6:24 pm
RNS
Filing of Form 20-F with SEC
  11:00 am
RNS
Annual Financial Report
06 Mar 2015 7:00 am
RNS
ASTRAZENECA REFINES ITS FINANCIAL REPORTING
04 Mar 2015 11:54 am
RNS
AZ TO PARTICIPATE IN US FDA EMDAC
03 Mar 2015 7:05 am
RNS
Acquisition of Rights to Actavis' Portfolio
02 Mar 2015 3:00 pm
RNS
Total Voting Rights
17 Feb 2015 7:00 am
RNS
Directorate Change
16 Feb 2015 7:00 am
RNS
PULMICORT RESPULES? US PATENT LITIGATION DECISION
05 Feb 2015 7:02 am
RNS
AZ to acquire Actavis' US respiratory portfolio
  7:00 am
RNS
Final Results
04 Feb 2015 9:00 am
RNS
Notice of Results
02 Feb 2015 2:00 pm
RNS
Total Voting Rights
22 Jan 2015 7:00 am
RNS
MAA FOR GOUT TREATMENT LESINURAD ACCEPTED BY EMA
14 Jan 2015 7:43 am
RNS
BRILINTA PEGASUS STUDY MEETS PRIMARY ENDPOINT
02 Jan 2015 2:00 pm
RNS
Total Voting Rights
19 Dec 2014 5:40 pm
RNS
LYNPARZA APPROVED BY THE US FDA
18 Dec 2014 7:00 am
RNS
LYNPARZAT APPROVED IN THE EUROPEAN UNION
09 Dec 2014 7:00 am
RNS
MOVENTIG approved in the EU for OIC
05 Dec 2014 5:03 pm
RNS
Jury verdict favours AZ in Nexium litigation
02 Dec 2014 7:00 am
RNS
New Drug Application for IRESSA accepted by US FDA
01 Dec 2014 2:00 pm
RNS
Blocklisting Interim Review
  2:00 pm
RNS
Total Voting Rights
26 Nov 2014 7:00 am
RNS
POSITIVE RESULTS FROM BRODALUMAB PHASE III STUDY
24 Nov 2014 4:00 pm
RNS
Publication of Final Terms
  7:00 am
RNS
DUAKLIR GENUAIR APPROVED IN THE EU FOR COPD
19 Nov 2014 5:00 pm
RNS
Launch and Pricing of a ?750m Bond
  9:41 am
RNS
Stabilisation Notice
18 Nov 2014 7:00 am
RNS
AZ strategy on track to deliver growth and value
17 Nov 2014 4:00 pm
RNS
Publication of Supplementary Prospectus
12 Nov 2014 7:00 am
RNS
AMGEN & AZ POSITIVE PHASE III BRODALUMAB RESULTS
10 Nov 2014 2:27 pm
RNS
Director/PDMR Shareholding
06 Nov 2014 7:04 am
RNS
ASTRAZENECA TO DIVEST MYALEPT TO AEGERION
  7:00 am
RNS
3rd Quarter Results
  7:00 am
RNS
3rd Quarter Results
05 Nov 2014 7:00 am
RNS
Notice of Results
04 Nov 2014 7:00 am
RNS
MEDIMMUNE ACQUIRES DEFINIENS
03 Nov 2014 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
AZ COMPLETES STRATEGIC TRANSACTION WITH ALMIRALL
30 Oct 2014 7:00 am
RNS
US FDA APPROVES ONCE-DAILY XIGDUOT XR TABLETS
24 Oct 2014 12:10 pm
RNS
Olaparib receives positive CHMP opinion
02 Oct 2014 3:30 pm
RNS
Director/PDMR Shareholding
01 Oct 2014 4:00 pm
RNS
Total Voting Rights
29 Sep 2014 7:00 am
RNS
ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ESMO
26 Sep 2014 11:15 am
RNS
Positive CHMP Opinion for MOVENTIG (naloxegol)
16 Sep 2014 4:27 pm
RNS
FDA Approves MOVANTIK (naloxegol) Tablets
  7:00 am
RNS
AZ AND LILLY ALLIANCE TO DEVELOP BACE INHIBITOR
10 Sep 2014 4:30 pm
RNS
Director/PDMR Shareholding
01 Sep 2014 4:00 pm
RNS
Total Voting Rights
19 Aug 2014 7:00 am
RNS
US DOJ Closes Investigation into Plato
  7:00 am
RNS
CAZ-AVI PHASE III RESULTS
14 Aug 2014 7:00 am
RNS
TRALOKINUMAB PHASE III START IN SEVERE ASTHMA
13 Aug 2014 7:00 am
RNS
PHASE III RESULTS LESINURAD COMBINATION THERAPY
04 Aug 2014 1:00 pm
RNS
Director/PDMR Shareholding
01 Aug 2014 2:00 pm
RNS
Total Voting Rights
  11:30 am
RNS
Director/PDMR Shareholding
31 Jul 2014 7:00 am
RNS
AstraZeneca Pipeline
  7:00 am
RNS
Second Quarter & Half Year Results 2014
30 Jul 2014 9:00 am
RNS
Notice of Results
  7:00 am
RNS
STRATEGIC RESPIRATORY TRANSACTION WITH ALMIRALL
01 Jul 2014 3:30 pm
RNS
Total Voting Rights
  12:00 pm
RNS
Director/PDMR Shareholding
26 Jun 2014 2:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
FDA Advisory Committee votes on olaparib
24 Jun 2014 5:30 pm
RNS
Publication of Prospectus
18 Jun 2014 11:00 am
RNS
Holding(s) in Company
  10:00 am
RNS
Director/PDMR Shareholding
  10:00 am
RNS
Director/PDMR Shareholding
13 Jun 2014 3:00 pm
RNS
Clarification of AXA shareholding in AstraZeneca
  7:00 am
RNS
FDA AdCom recommends no CV trial for PAMORA class
12 Jun 2014 7:00 am
RNS
ASTRAZENECA IN-LICENSES SYNAIRGEN'S SNG001
11 Jun 2014 7:00 am
RNS
AZ TO PRESENT NEW DATA AT ADA
03 Jun 2014 2:30 pm
RNS
ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ASCO
02 Jun 2014 2:00 pm
RNS
Blocklisting Interim Review
  1:30 pm
RNS
Total Voting Rights
29 May 2014 11:40 am
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  11:35 am
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  11:33 am
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
28 May 2014 11:51 am
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  11:49 am
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  11:48 am
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  11:48 am
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  11:48 am
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  11:39 am
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  11:38 am
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
27 May 2014 4:14 pm
BUS
Form 8.3 - Astrazeneca Plc
  4:04 pm
RNS
Form 8.3 - AstraZeneca PLC
  4:00 pm
RNS
Form 8.3 - Pfizer
  3:07 pm
BUS
Form 8.3 - AstraZeneca Plc
  2:58 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:38 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:30 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:26 pm
RNS
Form 8.3 - [Pfizer Inc]
  2:04 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  2:03 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  1:57 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:54 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:54 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:49 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:42 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:38 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:35 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:30 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:27 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:19 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:17 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  12:33 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  12:31 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  11:58 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:58 am
RNS
Form 8.5 (EPT/RI)
  11:57 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:55 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:55 am
RNS
Form 8.3 - Astrazeneca plc
  11:54 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:53 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:51 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:50 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:50 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:49 am
RNS
Form 8.5 (EPT/RI)
  11:47 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:47 am
RNS
Form 8.5 (EPT/RI)-AstraZeneca Plc
  11:46 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:46 am
RNS
Form 8.5 (EPT/RI)-AstraZeneca Plc
  11:45 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:44 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:19 am
RNS
Form 8.3 - AstraZeneca Plc
  10:47 am
RNS
Form 8.5 (EPT/RI)
  10:35 am
RNS
Form 8.3 - AstraZeneca Plc
  9:52 am
RNS
Rule 2.10 Announcement
  7:00 am
RNS
STATEMENT REGARDING PFIZER WITHDRAWAL
  7:00 am
RNS
ANNOUNCEMENT REGARDING ASTRAZENECA PLC
  7:00 am
RNS
Form 8.5 (EPT/RI)
  7:00 am
RNS
Form 8.5 (EPT/NON-RI)
  7:00 am
RNS
Form 8.3 - Pfizer Inc
  7:00 am
RNS
Form 8.3 - AstraZeneca Plc
  7:00 am
RNS
Form 8.3 - AstraZeneca Plc - Amendment
  7:00 am
RNS
Form 8.3 - AstraZeneca Plc - Amendment
  7:00 am
RNS
Form 8.3 - AstraZeneca Plc - Amendment
  7:00 am
RNS
Form 8.3 - AstraZeneca Plc - Amendment
23 May 2014 5:57 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:55 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:55 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:53 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  4:40 pm
RNS
Form 8.3 - AstraZeneca PLC
  4:37 pm
RNS
Form 8.3 - Pfizer Inc
  3:16 pm
BUS
Form 8.3 - Astrazenica Plc
  3:13 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:11 pm
RNS
Form 8.3 - [Astrazeneca Plc]
  3:02 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:51 pm
RNS
Form 8.3 - Pfizer Inc
  2:49 pm
RNS
Form 8.3 - Astrazeneca PLC
  2:48 pm
RNS
Form 8.3 - Pfizer Inc
  2:24 pm
RNS
Form 8.3 - Pfizer Inc
  2:23 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  2:22 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:20 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  2:19 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  2:19 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:16 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:45 pm
BUS
Form 8.3 - Astrazeneca Plc
  1:43 pm
BUS
Form 8.3 - AstraZeneca PLC
  1:03 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:36 pm
RNS
Form 8.3 - Pfizer Inc
  12:27 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:26 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:23 pm
RNS
Form 8.5 (EPT/NON-RI)-AstraZeneca Plc
  12:14 pm
RNS
Form 8.5 (EPT/NON-RI)
  12:11 pm
RNS
Form 8.5 (EPT/RI)
  11:45 am
RNS
Form 8.3 - [AstraZeneca plc]
  11:42 am
RNS
Form 8.5 (EPT/RI)-AstraZeneca Plc
  11:25 am
RNS
Form 8.3 - AstraZeneca Plc
  11:13 am
RNS
Form 8.5 (EPT/NON-RI)
  11:11 am
RNS
Form 8.5 (EPT/RI)
  11:00 am
RNS
Rule 2.10 Announcement
  10:55 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:54 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:53 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:51 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:51 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:48 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:48 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:47 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:07 am
RNS
Rule 2.10 Announcement
22 May 2014 6:17 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  6:11 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  3:53 pm
RNS
Form 8.3 - AstraZeneca PLC
  3:48 pm
RNS
Form 8.3 - Pfizer Inc
  3:22 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:16 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  3:08 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  3:08 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:03 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:02 pm
RNS
Form 8.3 - [Astrazeneca/Pfizer]
  3:01 pm
BUS
Form 8.3 - AstraZeneca Plc
  2:59 pm
RNS
Form 8.3 - Pfizer Inc
  2:55 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:33 pm
RNS
Form 8.3 - [AstraZeneca plc]
  2:15 pm
BUS
Form 8.3 - AstraZeneca PLC
  2:00 pm
RNS
Form 8.3 - Astrazeneca PLC
  1:59 pm
RNS
Form 8.3 - Pfizer Inc
  1:49 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  1:45 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  1:39 pm
RNS
Form 8.3 - Pfizer Inc
  1:39 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  1:29 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  1:23 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:18 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:14 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plz
  1:10 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:06 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazenec Plc
  1:01 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  12:53 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  12:48 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:27 pm
RNS
Form 8.5 (EPT/NON-RI)
  12:24 pm
RNS
Form 8.5 (EPT/RI)
  11:58 am
RNS
Form 8.5 (EPT/RI)-AstraZeneca Plc
  11:57 am
RNS
Form 8.5 (EPT/NON-RI)-AstraZeneca Plc
  11:53 am
RNS
Form 8.5 (EPT/NON-RI)-AstraZeneca Plc
  11:30 am
RNS
Form 8.3 - AstraZeneca Plc
  11:28 am
RNS
Form 8.5 (EPT/NON-RI)
  11:28 am
RNS
Form 8.5 (EPT/RI)
  11:00 am
RNS
Rule 2.10 Announcement
  10:58 am
RNS
Form 8.3 - Astrazeneca Plc
  10:56 am
BUS
Form 8.3 - Astrazeneca Plc
  10:50 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:50 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:47 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:47 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:42 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:42 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:41 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:40 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  9:21 am
RNS
Rule 2.10 Announcement
  7:00 am
RNS
Form 8.5 (EPT/NON-RI) - Amendment
  7:00 am
RNS
Form 8.5 (EPT/RI) - Amendment
21 May 2014 6:13 pm
RNS
Form 8.5 (EPT/RI)-AstraZeneca Plc-Amendment
  5:35 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:28 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  5:23 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  5:22 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  5:19 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  5:18 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  5:17 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  5:13 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  5:10 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  5:08 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  3:44 pm
RNS
Form 8.3 - Pfizer Inc
  3:37 pm
RNS
Form 8.3 - AstraZeneca PLC
  3:32 pm
RNS
Form 8.3 - Astrazeneca PLC
  3:29 pm
RNS
Form 8.3 - [AstraZeneca plc]
  3:17 pm
RNS
Form 8.3 -Pfizer Inc
  3:16 pm
RNS
Form 8.3 - [Astrazeneca/Pfizer]
  3:15 pm
RNS
Form 8.3 - Astrazeneca Plc
  3:09 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:03 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  3:02 pm
RNS
Form 8.5 (EPT/NON-RI) - AstraZeneca Plc
  2:59 pm
RNS
Form 8.5 (EPT/NON-RI) - AstraZeneca Plc
  2:59 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:59 pm
BUS
Form 8.3 - Astrazenica Plc
  2:56 pm
RNS
Form 8.3 - Pfizer Inc
  2:52 pm
RNS
Form 8.5 (EPT/NON-RI) - AstraZeneca Plc
  2:49 pm
RNS
Form 8.5 (EPT/NON-RI) - AstraZeneca Plc -Amendment
  2:48 pm
BUS
Form 8.3 - AstraZeneca Plc
  1:23 pm
RNS
Form 8.3 - Pfizer Inc
  1:22 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:38 pm
BUS
Form 8.3 - AstraZeneca PLC
  12:34 pm
BUS
Form 8.3 - Astrazeneca Plc
  12:07 pm
RNS
Form 8.5 (EPT/NON-RI) Amendment
  12:07 pm
RNS
Form 8.5 (EPT/RI)-AstraZeneca Plc
  12:02 pm
RNS
Form 8.5 (EPT/NON-RI)
  11:52 am
RNS
Form 8.5 (EPT/RI)
  11:49 am
RNS
Replacement - Form 8 (OPD) (Pfizer)
  11:49 am
RNS
Replacement - Form 8 (OPD) (Pfizer)
  11:33 am
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  11:33 am
RNS
Form 8.3 - AstraZeneca Plc
  11:29 am
RNS
Rule 2.10 Announcement
  11:28 am
RNS
Form 8.5 (EPT/NON-RI)
  11:22 am
RNS
Form 8.5 (EPT/RI)
  11:09 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:08 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:07 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:04 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:03 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:01 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:00 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:32 am
RNS
Rule 2.10 Announcement
  10:27 am
RNS
Form 8.3 - Astrazeneca Plc
  7:00 am
RNS
Form 8.5 (EPT/NON-RI) - AstraZeneca Plc
20 May 2014 6:17 pm
RNS
CLARIFICATION REGARDING PFIZER STATEMENT
  5:01 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  4:59 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  4:54 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  4:52 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  4:32 pm
BUS
Form 8.3 - Astrazenica Plc
  3:22 pm
RNS
Form 8.3 - AstraZeneca Inc
  3:16 pm
RNS
Form 8.3 - Pfizer Inc
  3:13 pm
RNS
Form 8.3 - [AstraZeneca PLC]
  3:09 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:01 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:59 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  2:58 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  2:57 pm
RNS
Form 8.3 - [AstraZeneca PLC]
  2:56 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  2:55 pm
RNS
Form 8.3 - Pfizer Inc
  2:52 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  2:52 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  2:48 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  2:30 pm
RNS
Form 8.3 - Astrazeneca PLC
  2:28 pm
RNS
Form 8.3 - Pfizer Inc
  2:27 pm
BUS
Form 8.3 - AstraZeneca Plc
  2:01 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:51 pm
BUS
Form 8.3 - AstraZeneca PLC
  1:23 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:20 pm
RNS
Form 8.3 - Pfizer Inc
  1:19 pm
RNS
Form 8.3 - Pfizer Inc
  1:14 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:39 pm
RNS
Form 8.5 (EPT/RI)
  12:38 pm
RNS
Form 8.5 (EPT/NON-RI)
  12:35 pm
RNS
Form 8.5 (EPT/RI)-AstraZeneca Plc
  12:11 pm
RNS
Form 8.3 - [AstraZeneca plc]
  12:02 pm
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  12:02 pm
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  12:02 pm
RNS
Form 8.5 (EPT/RI) - Pfizer Inc
  11:59 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:58 am
RNS
Form 8.5 (EPT/RI) - Astrazeneca Plc
  11:56 am
RNS
Form 8.5 (EPT/NON-RI)
  11:55 am
RNS
Form 8.3 - Astrazeneca plc
  11:54 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:53 am
RNS
Form 8.5 (EPT/RI)
  11:53 am
BUS
Form 8.3 - Astrazeneca Plc
  11:48 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:48 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:00 am
RNS
Rule 2.10 Announcement
  10:59 am
RNS
Replacement: Final Proposal to AstraZeneca
  10:49 am
RNS
Form 8.3 - Astrazeneca Plc
  9:47 am
RNS
Rule 2.10 Announcement
19 May 2014 5:51 pm
RNS
Form 8.5 (EPT/NON-RI) - Amendment
  5:49 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:45 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:39 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:06 pm
RNS
Form 8.5 (EPT/RI) - AstraZeneca Plc - Amendment
  3:32 pm
RNS
Form 8.3 - AstraZeneca PLC
  3:31 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:28 pm
RNS
Form 8.3 - Astrazeneca Plc
  3:27 pm
RNS
Form 8.3 - Pfizer Inc
  3:26 pm
BUS
Form 8.3 - Astrazenica Plc
  3:23 pm
RNS
Form 8.3 - Astrazeneca PLC
  3:16 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:14 pm
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  3:10 pm
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  3:09 pm
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  3:09 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:08 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  2:44 pm
RNS
Form 8.3 - Pfizer Inc
  1:13 pm
BUS
Form 8.3 - AstraZeneca PLC
  1:01 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:59 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:55 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:53 pm
RNS
Form 8.3 - Pfizer Inc
  12:24 pm
RNS
Form 8.5 (EPT/NON-RI) Replacement
  12:19 pm
RNS
Form 8.5 (EPT/RI)
  12:03 pm
RNS
Form 8.3 - Astrazeneca Plc
  11:37 am
RNS
Form 8.5 (EPT/NON-RI)
  11:34 am
RNS
Form 8.5 (EPT/RI)
  11:18 am
BUS
Form 8.3 - Astrazeneca Plc
  11:12 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:10 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:10 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:09 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:08 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:07 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:07 am
RNS
Form 8.3 - [AstraZeneca plc]
  11:07 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:04 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:00 am
RNS
Rule 2.10 Announcement
  10:48 am
RNS
Form 8.5 (EPT/RI) - AstraZeneca
  9:22 am
RNS
Rule 2.10 Announcement
  7:08 am
RNS
ASTRAZENECA BOARD REJECTS PFIZER'S FINAL PROPOSAL
  7:00 am
RNS
PFIZER MAKES FINAL PROPOSAL TO ASTRAZENECA
  7:00 am
RNS
Form 8.3 - AstraZeneca Plc - Replacement
  7:00 am
RNS
Form 8.3 - AstraZeneca Plc
  7:00 am
RNS
Form 8.3 - AstraZeneca Plc - Replacement
  7:00 am
RNS
Form 8.3 - AstraZeneca Plc - Replacement
16 May 2014 5:00 pm
RNS
Form 8.3 - Replacement Pfizer Inc
  4:59 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  4:57 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  4:54 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  4:53 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  4:05 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:54 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:48 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:46 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:43 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:39 pm
RNS
Form 8.3 - AstraZeneca PLC
  3:29 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:14 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:05 pm
RNS
Form 8.3 - AstraZeneca PLC
  3:01 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  2:50 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:40 pm
BUS
Form 8.3 - AstraZeneca Plc
  2:39 pm
RNS
Form 8.3 - Pfizer Inc
  2:32 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:31 pm
RNS
Form 8.3 - [Pfizer Inc]
  1:54 pm
BUS
Form 8.3 - AstraZeneca PLC
  1:25 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:59 pm
BUS
Form 8.3 - Astrazeneca Plc
  12:32 pm
RNS
Form 8.5 (EPT/RI)AMENDMENTS
  12:31 pm
RNS
Form 8.3 - [AstraZeneca plc]
  12:26 pm
RNS
Form 8.3 - Pfizer Inc
  12:24 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:24 pm
RNS
Form 8.3 - AstraZeneca Plc
  11:55 am
RNS
Form 8.3 - Astrazeneca plc
  11:50 am
RNS
Form 8.5 (EPT/RI) - AstraZeneca Plc
  11:46 am
RNS
Form 8.5 (EPT/NON-RI)
  11:44 am
RNS
Form 8.5 (EPT/RI)
  11:41 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:40 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:38 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:34 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:33 am
RNS
Form 8.5 (EPT/RI) Pfizer INc
  11:17 am
RNS
Form 8.3 - AstraZeneca PLC
  11:13 am
RNS
Form 8.5 (EPT/RI)
  11:00 am
RNS
Rule 2.10 Announcement
  9:18 am
RNS
Rule 2.10 Announcement
  7:00 am
RNS
Form 8.5 (EPT/RI) - Amendment
  7:00 am
RNS
Form 8.5 (EPT/RI) - Amendment
  7:00 am
RNS
Form 8.5 (EPT/RI) - Amendment
15 May 2014 6:20 pm
RNS
Form 8.5 (EPT/RI) - AstraZeneca Plc - Amendment
  6:13 pm
RNS
Form 8.5 (EPT/RI) - AstraZeneca Plc - Amendment
  6:11 pm
RNS
Form 8.5 (EPT/RI) - AstraZeneca Plc - Amendment
  6:11 pm
RNS
Form 8.5 (EPT/RI) - AstraZeneca Plc - Amendment
  6:08 pm
RNS
Form 8.5 (EPT/RI) - AstraZeneca Plc - Amendment
  6:04 pm
RNS
Form 8.5 (EPT/RI) -AstraZeneca Plc - Amendment
  5:59 pm
RNS
Form 8.5 (EPT/RI) AstraZeneca Plc - Amendment
  5:52 pm
RNS
Form 8.3 - Pfizer Inc
  5:50 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:50 pm
RNS
Form 8.3 - Pfizer Inc
  3:28 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:26 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  3:24 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  3:23 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:22 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:22 pm
RNS
Form 8.3 - Pfizer Inc
  3:19 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:16 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:10 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:10 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  3:02 pm
BUS
Form 8.3 - AstraZeneca Plc
  2:51 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:29 pm
RNS
Form 8.3 - [Pfizer Inc]
  1:57 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:54 pm
RNS
Form 8.3 - AstraZeneca PLC
  1:52 pm
RNS
CONTINUING PROGRESS IN LATE STAGE PIPELINE
  1:34 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:26 pm
RNS
Form 8.3 - Pfizer Inc
  1:23 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:56 pm
BUS
Form 8.3 - AstraZeneca PLC
  12:51 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:39 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  12:35 pm
RNS
Form 8.3 - [AstraZeneca plc]
  12:15 pm
RNS
Form 8.5 (EPT/NON-RI)
  12:10 pm
RNS
Form 8.5 (EPT/RI)
  12:06 pm
BUS
Form 8.3 - Astrazeneca Plc - Amendment
  11:55 am
RNS
Form 8.3 - AstraZeneca plc
  11:49 am
RNS
Form 8.5 (EPT/RI)
  11:48 am
RNS
Form 8.5 (EPT/NON-RI)
  11:35 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:35 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:35 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:31 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:28 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:27 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:27 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:26 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:03 am
RNS
Form 8.5 (EPT/RI) - AstraZeneca
  11:03 am
RNS
Form 8.3 - AstraZeneca PLC
  11:00 am
RNS
Rule 2.10 Announcement
  9:39 am
RNS
Rule 2.10 Announcement
  7:00 am
RNS
AstraZeneca oncology pipeline update ahead of ASCO
14 May 2014 6:28 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  6:27 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  6:21 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  6:01 pm
RNS
Form 8.5 (EPT/RI) - Pfizer INC
  4:48 pm
RNS
Form 8.3 - Replacement - Pfizer Inc
  3:27 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  3:25 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:23 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:23 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:22 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  3:20 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Inc
  3:20 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:16 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:07 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:01 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  3:00 pm
BUS
Form 8.3 - AstraZeneca Plc
  2:59 pm
RNS
Form 8.3 - [Pfizer Inc]
  2:57 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:54 pm
RNS
Form 8.3 - [AstraZeneca plc]
  2:35 pm
RNS
Form 8.3 - Pfizer Inc
  2:08 pm
RNS
Form 8.3 - Astrazeneca Plc
  1:28 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:58 pm
BUS
Form 8.3 - AstraZeneca PLC
  12:51 pm
RNS
Form 8.3 - Pfizer Inc
  12:47 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:39 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:26 pm
RNS
Form 8.5 (EPT/RI)
  12:08 pm
RNS
Form 8.5 (EPT/NON-RI)
  11:55 am
RNS
Form 8.3 - AstraZeneca plc
  11:34 am
RNS
Form 8.5 (EPT/NON-RI)
  11:30 am
RNS
Form 8.5 (EPT/RI)
  11:22 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:21 am
RNS
Form 8.3 - AstraZeneca PLC
  11:21 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:20 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:16 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  11:14 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:13 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:12 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:12 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:07 am
RNS
Form 8.5 (EPT/RI) - AstraZeneca
  11:01 am
BUS
Form 8.3 - Astrazeneca Plc - Amendment
  11:00 am
RNS
Rule 2.10 Announcement
  10:54 am
RNS
Rule 2.10 Announcement
  7:00 am
RNS
MedImmune announces immuno-oncology collaboration
13 May 2014 5:21 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:19 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:18 pm
BUS
Form 8.3 - Astrazeneca Plc - Amendment
  5:10 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:08 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:00 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  4:59 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  3:32 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:28 pm
RNS
Form 8.3 - [Pfizer Inc]
  3:12 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:06 pm
BUS
Form 8.3 - AstraZeneca Plc
  2:55 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:53 pm
RNS
Form 8.3 - [Pfizer Inc]
  2:52 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  2:51 pm
RNS
Form 8.3 - Pfizer Inc
  2:43 pm
BUS
Form 8.3 - Astrazenica Plc
  2:19 pm
RNS
Form 8.3 -Astrazeneca Plc
  2:11 pm
RNS
Form 8.3 - Pfizer Inc
  1:49 pm
RNS
Form 8.3 - [AstraZeneca plc]
  1:22 pm
RNS
Form 8.3 - AstraZeneca PLC
  1:19 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:59 pm
BUS
Form 8.3 - AstraZeneca PLC
  12:57 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  12:56 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  12:52 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  12:50 pm
RNS
Form 8.5 (EPT/RI) - AstraZeneca
  12:49 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  12:48 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  12:46 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  12:43 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  12:38 pm
RNS
Form 8.5 (EPT/NON-RI)
  12:34 pm
RNS
Form 8.5 (EPT/RI)
  12:20 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:10 pm
RNS
Form 8.3 - Pfizer Inc
  12:05 pm
RNS
Form 8.3 - AstraZeneca Plc
  11:59 am
RNS
Form 8.5 (EPT/RI) - Astrazeneca Plc
  11:41 am
RNS
Form 8.5 (EPT/RI) - Pfizer Inc
  11:39 am
RNS
Form 8.5 (EPT/RI) - Pfizer Inc
  11:38 am
RNS
Form 8.5 (EPT/NON-RI)
  11:38 am
RNS
Form 8.5 (EPT/RI) - Pfizer Inc
  11:38 am
RNS
Form 8.5 (EPT/RI) - Pfizer Inc
  11:37 am
RNS
Form 8.5 (EPT/RI)
  11:36 am
RNS
Form 8.5 (EPT/RI) - Astrazeneca Plc
  11:31 am
RNS
Rule 2.10 Announcement
  11:31 am
RNS
Form 8.5 (EPT/RI) - Astrazeneca Plc
  11:30 am
RNS
Form 8.5 (EPT/RI) - Astrazeneca Plc
  11:17 am
BUS
Form 8.3 - Astrazeneca Plc - AMENDMENT
  11:15 am
RNS
STATEMENT REGARDING PFIZER ANNOUNCEMENT
  11:00 am
RNS
Rule 2.10 Announcement
  10:57 am
BUS
Form 8.3 - Astrazeneca Plc
  10:21 am
RNS
Replacement: Possible offer for AstraZeneca
  7:00 am
RNS
AZ PHASE III SAXA/DAPA RESULTS
12 May 2014 6:15 pm
RNS
Form 8 (OPD) AstraZeneca PLC
  6:11 pm
RNS
Form 8 (OPD)
  6:06 pm
RNS
Form 8 (OPD)
  5:34 pm
RNS
Form 8.3 - Pfizer Amendment change to section 2
  4:01 pm
RNS
AZ ANNOUNCES RESULTS OF PHASE IIB STUDIES
  4:00 pm
RNS
AZ TO PRESENT DATA AT ATS 2014
  3:42 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  3:41 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  3:40 pm
RNS
Form 8.5 (EPT/RI) - Replacement Astrazeneca Plc
  3:36 pm
RNS
Form 8.3 - [Pfizer/AstraZeneca]
  3:25 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:09 pm
BUS
Form 8.3 - Astrazenica Plc
  3:03 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:59 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:50 pm
RNS
Form 8.3 - Pfizer Inc
  2:47 pm
RNS
Form 8.3 - [Astrazeneca Plc]
  2:30 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:20 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:18 pm
RNS
Form 8.3 - [Pfizer Inc]
  2:03 pm
RNS
Form 8.5 (EPT/NON-RI)
  1:58 pm
BUS
Form 8.3 - AstraZeneca PLC
  1:26 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:14 pm
RNS
Form 8.3 - Pfizer Inc
  1:00 pm
RNS
Statement re R&D Comments on Combination
  12:33 pm
RNS
Form 8.3 - [AstraZeneca plc]
  12:26 pm
RNS
Form 8.5 (EPT/RI)
  12:12 pm
BUS
Form 8.3 - Astrazeneca Plc
  11:41 am
RNS
Form 8.5 (EPT/RI) - Astrazeneca Plc
  11:39 am
RNS
Form 8.5 (EPT/NON-RI)
  11:39 am
RNS
Form 8.5 (EPT/RI)
  11:38 am
RNS
Rule 2.10 Announcement
  11:38 am
RNS
Form 8.5 (EPT/RI) - Astrazeneca Plc
  11:36 am
RNS
Form 8.5 (EPT/RI) - Astrazeneca Plc
  11:34 am
RNS
Form 8.5 (EPT/RI) - Pfizer Inc
  11:32 am
RNS
Form 8.5 (EPT/RI) - Pfizer Inc
  11:31 am
RNS
Form 8.5 (EPT/RI) - Pfizer Inc
  11:30 am
RNS
Form 8.5 (EPT/RI) - Astrazeneca Plc
  11:26 am
RNS
Form 8.5 (EPT/RI) - Pfizer Inc
  11:16 am
RNS
Form 8.3 - AstraZeneca PLC
  11:00 am
RNS
Rule 2.10 Announcement
  10:53 am
RNS
Form 8.3 - Pfizer Inc
  10:52 am
RNS
Form 8.3 - AstraZeneca Plc
  7:00 am
RNS
THE BENEFITS OF A POTENTIAL COMBINATION
  7:00 am
RNS
AMGEN & AZ BRODALUMAB PHASE III RESULTS
  7:00 am
RNS
Form 8.5 (EPT/RI) AMENDMENT
09 May 2014 6:23 pm
RNS
Form 8.3 - Pfizer Inc - Amendment
  6:20 pm
RNS
Form 8.3 - Pfizer Inc
  6:06 pm
RNS
Form 8.5 (EPT/RI) Pfizer INC
  3:38 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:37 pm
RNS
Form 8.5 (EPT/RI) - AstraZeneca Plc
  3:28 pm
RNS
Form 8.3 - Astrazeneca Plc
  3:11 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:11 pm
RNS
Form 8.3 - Pfizer INC
  3:10 pm
RNS
Form 8.3 - Astrazeneca PLC
  2:29 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  2:26 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  2:24 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  2:21 pm
RNS
Form 8 (OPD) - AstraZeneca PLC
  2:20 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  2:20 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  2:15 pm
BUS
Form 8.3 - Astrazeneca Plc
  2:06 pm
BUS
Form 8.3 - AstraZeneca Plc
  1:58 pm
RNS
Form 8.5 (EPT/RI) Replacement Pfizer Inc
  1:56 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  1:54 pm
RNS
Form 8.5 (EPT/RI) Replacement Astrazeneca Plc
  1:54 pm
BUS
Form 8.3 - AstraZeneca PLC
  1:53 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  1:50 pm
RNS
Form 8.5 (EPT/RI)Replacement - Astrazeneca PLC
  1:44 pm
RNS
Form 8.5 (EPT/NON-RI) Replacement - Pfizer INC
  1:43 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:09 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:08 pm
RNS
Form 8.3 - Pfizer
  12:35 pm
RNS
Form 8.3 - Pfizer Inc
  12:24 pm
RNS
Form 8.5 (EPT/NON-RI)
  12:21 pm
RNS
Form 8.5 (EPT/RI)
  12:19 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:12 pm
RNS
Form 8.3 - Pfizer Inc
  12:11 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:08 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:07 pm
RNS
Form 8.3 - [Pfizer Inc]
  11:56 am
RNS
Form 8.3 - [AstraZeneca plc]
  11:55 am
RNS
Form 8.3 - AstraZeneca plc
  11:43 am
BUS
Form 8.3 - Astrazeneca Plc
  11:34 am
RNS
Form 8.5 (EPT/RI)
  11:25 am
RNS
Form 8.5 (EPT/NON-RI)
  11:24 am
RNS
Form 8.5 (EPT/RI)
  11:22 am
RNS
Form 8.3 - AstraZeneca PLC
  11:00 am
RNS
Rule 2.10 Announcement
  10:53 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:51 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:50 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:49 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:47 am
RNS
Form 8.5 (EPT/RI) Pfizer INC
  10:45 am
RNS
Form 8.5 (EPT/RI) Pfizer INC
  10:44 am
RNS
Form 8.5 (EPT/RI) Pfizer INC
  9:56 am
RNS
Rule 2.10 Announcement
  7:00 am
RNS
Form 8.5 (EPT/RI) - Amendment
  7:00 am
RNS
Form 8.5 (EPT/NON-RI) - Amendment
  7:00 am
RNS
Form 8.5 (EPT/RI) - Amendment
  7:00 am
RNS
Form 8.5 (EPT/RI) - Amendment
  7:00 am
RNS
Form 8.5 (EPT/RI) - Amendment
08 May 2014 4:49 pm
RNS
Form 8.5 (EPT/RI)Replacement - Astrazeneca PLC
  4:35 pm
RNS
Form 8.5 (EPT/RI)Replacement - Astrazeneca PLC
  4:33 pm
RNS
Form 8.5 (EPT/RI) - Astrazeneca PLC
  4:28 pm
RNS
Form 8.5 (EPT/RI)Replacement - Astrazeneca PLC
  4:27 pm
RNS
Form 8.5 (EPT/RI)Replacement - Pfizer INC
  4:25 pm
RNS
Form 8.5 (EPT/RI)Replacement - Pfizer INC
  4:23 pm
BUS
Form 8.3 - AstraZeneca Plc
  4:21 pm
RNS
Form 8.5 (EPT/RI)- Replacement - Pfizer INC
  4:19 pm
RNS
Form 8.5 (EPT/RI)Replacement - Pfizer INC
  4:15 pm
RNS
Form 8.5 (EPT/RI)Replacement - Pfizer INC
  3:18 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:16 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:53 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:52 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:47 pm
RNS
Form 8.3 - Pfizer Inc
  2:32 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:32 pm
RNS
Form 8.3 - AstraZeneca PLC
  2:27 pm
RNS
Form 8.3 - Astrazeneca Plc
  2:08 pm
BUS
Form 8.3 - Astrazeneca Plc
  2:02 pm
RNS
Form 8.3 - Astrazeneca PLC
  2:01 pm
RNS
Form 8.3 - Pfizer Inc
  1:58 pm
RNS
Form 8.3 - [AstraZeneca plc]
  1:07 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:03 pm
RNS
Form 8.3 - Pfizer Inc
  12:54 pm
BUS
Form 8.3 - AstraZeneca PLC
  12:38 pm
RNS
Form 8.5 (EPT/RI) - AstraZeneca Plc
  12:33 pm
RNS
Form 8.5 (EPT/RI)
  12:31 pm
RNS
ASTRAZENECA INITIATES PHASE III STUDY FOR MEDI4736
  12:01 pm
RNS
Form 8.5 (EPT/NON-RI)
  11:57 am
RNS
Form 8.5 (EPT/RI)
  11:55 am
RNS
Form 8.3 - AstraZeneca plc
  11:32 am
BUS
Form 8.3 - Astrazeneca Plc
  11:21 am
RNS
Form 8.3 - [Pfizer Inc]
  11:20 am
RNS
Form 8.3 - [AstraZeneca Plc]
  11:10 am
RNS
Form 8.3 - AstraZeneca PLC
  11:02 am
RNS
Rule 2.10 Announcement
  10:46 am
RNS
Form 8.5 (EPT/RI) Replacement - Pfizer INC
  10:45 am
RNS
Form 8.5 (EPT/RI)Replacement - Pfizer INC
  10:45 am
RNS
Form 8.5 (EPT/RI) Replacement - Pfizer INC
  10:39 am
RNS
Form 8.5 (EPT/RI)Replacement - Astrazeneca PLC
  10:27 am
RNS
Form 8.5 (EPT/RI)Replacement - Astrazeneca PLC
  10:24 am
RNS
Form 8.5 (EPT/RI)- Replacement - Astrazeneca PLC
  10:24 am
RNS
Form 8.5 (EPT/RI) Replacement - Astrazeneca PLC
  10:22 am
RNS
Form 8.5 (EPT/RI) Replacement - Astrazeneca PLC
  10:18 am
RNS
Form 8.5 (EPT/RI) Replacement - Astrazeneca PLC
  10:15 am
RNS
Form 8.5 (EPT/RI)Replacement - Pfizer INC
  10:13 am
RNS
Form 8.5 (EPT/RI)Replacement Pfizer INC
  10:12 am
RNS
Form 8.5 (EPT/RI) Astrazenenca PLC
  10:09 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:08 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:07 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:06 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:05 am
RNS
Form 8.5 (EPT/RI)Pfizer INC
  9:53 am
RNS
Rule 2.10 Announcement
07 May 2014 5:30 pm
RNS
Holding(s) in Company
  5:24 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:06 pm
RNS
Form 8.3 - [Astrazeneca/Pfizer]
  5:03 pm
RNS
Form 8.3 - [Astrazeneca/Pfizer] amendment s.2
  5:01 pm
RNS
Form 8.3 - [Astrazeneca/Pfizer] amendment s.2
  4:59 pm
RNS
Form 8.3 - [Astrazeneca/Pfizer] amendment s.2
  4:56 pm
RNS
Form 8.3 - [Astrazeneca/Pfizer] amendment s.2
  4:56 pm
BUS
Form 8.3 - Astrazeneca Plc
  3:53 pm
RNS
Form 8.3 - [AstraZeneca plc]
  3:45 pm
RNS
Form 8.3 - PFIZER INC
  3:33 pm
RNS
Form 8.3 - Pfizer Inc
  3:27 pm
RNS
Form 8.3 - Pfizer Inc Amendment
  3:27 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:24 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:10 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  3:04 pm
RNS
Form 8.3 - [PFIZER INC]
  3:00 pm
RNS
Form 8.3 - AstraZeneca PLC
  2:50 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:37 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:24 pm
RNS
Form 8.5 (EPT/RI) - Astrazenica Plc
  2:20 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:41 pm
BUS
Form 8.3 - AstraZeneca PLC
  1:39 pm
BUS
Form 8.3 - Astrazenica Plc
  1:38 pm
RNS
Form 8.3 - Pfizer Inc
  1:23 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:32 pm
RNS
Form 8.5 (EPT/NON-RI)
  12:26 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:23 pm
RNS
Form 8.5 (EPT/RI)
  12:03 pm
RNS
Form 8.3 - AstraZeneca Plc
  11:55 am
RNS
Form 8.3 - AstraZeneca, plc
  11:33 am
RNS
Form 8.5 (EPT/RI)
  11:25 am
RNS
Form 8.3 - AstraZeneca PLC
  11:18 am
BUS
Form 8.3 - Astrazeneca Plc
  11:17 am
RNS
Form 8.5 (EPT/RI)
  11:16 am
RNS
Form 8.5 (EPT/NON-RI)
  11:00 am
RNS
Rule 2.10 Announcement
  10:40 am
RNS
Form 8.5 (EPT/RI) astrazeneca PLC
  10:39 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:38 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:36 am
RNS
Form 8.5 (EPT/RI) Pfizer INC
  10:33 am
RNS
Form 8.5 (EPT/RI) Pfizer INC
  10:32 am
RNS
Form 8.5 (EPT/RI) Pfizer INC
  10:31 am
RNS
Rule 2.10 Announcement
  10:30 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:29 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  7:00 am
RNS
BENEFITS OF A COMBINATION WITH ASTRAZENECA
  7:00 am
RNS
Form 8.5 (EPT/NON-RI)
06 May 2014 6:12 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  6:07 pm
RNS
Form 8.5 (EPT/NON-RI)(OPD)
  4:30 pm
RNS
Form 8.3 - AstraZeneca Plc
  4:29 pm
RNS
Form 8.3 - AstraZeneca Plc
  4:16 pm
RNS
Form 8.5 (EPT/RI)replacement - Pfizer Inc
  4:14 pm
RNS
Form 8.5 (EPT/RI) Replacement - Pfizer Inc
  4:11 pm
RNS
Form 8.5 (EPT/RI)Replacement - Pfizer Inc
  4:07 pm
RNS
Form 8.5 (EPT/RI)Replacement - Pfizer Inc
  4:05 pm
RNS
Form 8.5 (EPT/RI) Replacement - Pfizer Inc
  4:04 pm
RNS
Form 8.5 (EPT/RI)replacement - Pfizer Inc
  4:02 pm
BUS
Form 8.3 - ASTRAZENECA PLC
  3:56 pm
RNS
Form 8.5 (EPT/RI)Replacement - Astrazeneca PLC
  3:54 pm
RNS
Form 8.5 (EPT/RI)Replacement Astrazenenca PLC
  3:53 pm
RNS
Form 8.5 (EPT/RI) Replacement - Astrazeneca PLC
  3:51 pm
RNS
Form 8.5 (EPT/RI)Replacement - Astrazeneca PLC
  3:49 pm
RNS
Form 8.5 (EPT/RI) Replacement - Astrazeneca PLC
  3:46 pm
RNS
Form 8.5 (EPT/RI)replacement - Astrazeneca PLC
  3:30 pm
RNS
Changes to membership of Board Committees
  3:26 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:24 pm
RNS
Form 8.3 - AstraZeneca PLC
  3:22 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:19 pm
RNS
Form 8.3 - Pfizer Inc
  3:18 pm
RNS
Form 8.3 - astrazeneca plc
  3:17 pm
RNS
Form 8.3 - AstraZeneca PLC
  3:16 pm
RNS
Form 8.3 - AstraZeneca plc
  3:16 pm
RNS
Form 8.3 - PFIZER INC
  3:15 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:12 pm
BUS
Form 8.3 - AstraZeneca Plc
  2:49 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:26 pm
RNS
Form 8.3 - [Astrazeneca/Pfizer]
  2:12 pm
RNS
Form 8.3 - [Pfizer Inc]
  1:54 pm
RNS
Form 8.3 - Pfizer Inc
  1:48 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:28 pm
RNS
Form 8.3 - Pfizer Inc
  1:25 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:20 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  1:13 pm
RNS
Form 8.5 (EPT/RI)
  1:12 pm
BUS
Form 8.3 - AstraZeneca PLC
  1:10 pm
BUS
Form 8.3 - AstraZeneca PLC
  1:06 pm
RNS
Form 8.5 (EPT/RI)
  12:35 pm
RNS
Form 8.5 (EPT/NON-RI)
  12:31 pm
BUS
Form 8.3 - Astrazeneca Plc
  12:21 pm
RNS
Form 8.5 (EPT/RI) - Astrazeneca Plc
  11:55 am
RNS
Form 8.3 - AstraZeneca plc
  11:48 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  11:47 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  11:44 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  11:44 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  11:42 am
RNS
Rule 2.10 Announcement
  11:40 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:37 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:36 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:33 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:30 am
RNS
Rule 2.10 Announcement
  11:03 am
RNS
Form 8.5 (EPT/RI)
  11:02 am
RNS
Form 8.5 (EPT/NON-RI)
  11:00 am
RNS
ASTRAZENECA ISSUES UPDATE ON STRATEGY
  10:47 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:42 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  7:01 am
RNS
US FDA APPROVES EPANOVA
  7:01 am
RNS
Form 8.5 (EPT/RI) - Amendment
  7:01 am
RNS
Form 8.3 - AstraZeneca Plc
  7:01 am
RNS
Form 8.3 - [ASTRAZENECA PLC]
  7:01 am
RNS
Form 8.3 - AstraZeneca Plc
  7:01 am
RNS
Form 8.5 (EPT/NON-RI)
  7:01 am
RNS
Form 8.5 (EPT/RI)
  7:01 am
RNS
Form 8.5 (EPT/NON-RI)
  7:00 am
BUS
Form 8.3 - AstraZeneca Plc
  7:00 am
BUS
Form 8.3 - Astrazeneca - Amendment
02 May 2014 6:14 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  6:01 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  5:59 pm
RNS
Form 8.5 (EPT/RI) - Amendment
  4:11 pm
RNS
Form 8.3 - AstraZeneca PLC
  4:07 pm
BUS
Form 8.3 - AstraZeneca
  3:36 pm
RNS
Form 8.5 (EPT/NON-RI)
  3:34 pm
RNS
Form 8.5 (EPT/RI)
  3:21 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:06 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:02 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:42 pm
RNS
Form 8.3 - AstraZenca PLC
  2:41 pm
RNS
Form 8.3 - PFIZER INC
  2:29 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:26 pm
RNS
Form 8.3 - Pfizer Inc
  2:24 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:24 pm
BUS
Form 8.3 - Astrazeneca Plc
  2:23 pm
RNS
Form 8.5 (EPT/RI) - Replacement - Astrazeneca Plc
  2:20 pm
RNS
Form 8.5 (EPT/RI) - Replacement - Astrazeneca Plc
  2:18 pm
RNS
Form 8.5 (EPT/RI) - Replacement - Astrazeneca Plc
  2:16 pm
RNS
Form 8.5 (EPT/RI) - Replacement - Pfizer Inc
  2:12 pm
RNS
Form 8.5 (EPT/RI) - Replacement - Pfizer Inc
  2:10 pm
RNS
Form 8.5 (EPT/RI) - Replacement - Pfizer Inc
  2:07 pm
RNS
Form 8.5 (EPT/RI) - Replacement - Pfizer Inc
  1:58 pm
RNS
Form 8.5 (EPT/RI) - Replacement - Pfizer Inc
  1:41 pm
BUS
Form 8.3 - AstraZeneca PLC
  1:07 pm
RNS
Form 8.3 - Pfizer Inc
  1:03 pm
RNS
Form 8.3 - AstraZeneca Plc
  12:57 pm
RNS
Form 8.3 - [AstraZeneca plc]
  12:34 pm
RNS
Form 8.5 (EPT/RI)-Pfizer Inc.
  12:33 pm
RNS
Form 8.5 (EPT/RI)-AstraZeneca Plc
  12:25 pm
RNS
Form 8.3 - AstraZeneca PLC
  12:17 pm
RNS
Form 8.5 (EPT/NON-RI)
  12:04 pm
RNS
Form 8.5 (EPT/RI)
  11:55 am
RNS
Form 8.3 - AstraZeneca plc
  11:51 am
RNS
Form 8.3 - AstraZeneca Plc
  11:01 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  11:00 am
RNS
Rule 2.10 Announcement
  10:59 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:59 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:57 am
RNS
Form 8.5 (EPT/RI) Pfizer INC
  10:56 am
RNS
Form 8.5 (EPT/RI) Pfizer INC
  10:52 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  10:50 am
RNS
ASTRAZENECA BOARD REJECTS PFIZER PROPOSAL
  8:09 am
RNS
STATEMENT REGARDING PFIZER ANNOUNCEMENT
  7:00 am
RNS
PFIZER SENDS LETTER TO RT HON DAVID CAMERON MP
  7:00 am
RNS
Statement re Possible Offer
  7:00 am
RNS
Form 8.5 (EPT/NON-RI)
  7:00 am
RNS
Form 8.5 (EPT/NON-RI)
  7:00 am
RNS
Form 8.5 (EPT/RI) - Amendment
01 May 2014 6:04 pm
RNS
Form 8.5 (EPT/NON-RI)-Amendment
  5:35 pm
RNS
Form 8.5 (EPT/RI)
  5:35 pm
RNS
Form 8.5 (EPT/NON-RI)
  4:47 pm
BUS
Form 8.3- ASTRAZENECA PLC
  3:46 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:36 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:31 pm
RNS
Form 8.3 - Pfizer Inc
  3:29 pm
RNS
Form 8.3 - [AstraZeneca plc]
  3:28 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:28 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:17 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  3:13 pm
RNS
Form 8.3 - AstraZeneca PLC
  3:03 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:00 pm
RNS
Form 8.3 - Pfizer Inc
  2:55 pm
RNS
Form 8.3 - [AstraZeneca PLC]
  2:46 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  2:31 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:18 pm
RNS
Form 8.5 (EPT/RI)- replacement - Pfizer Inc
  2:13 pm
RNS
Form 8.5 (EPT/RI) - replacement - Pfizer Inc
  2:11 pm
RNS
Form 8.5 (EPT/RI) - replacement - Astrazeneca Plc
  2:06 pm
RNS
Form 8.5 (EPT/RI) - replacement - Astrazeneca Plc
  2:05 pm
RNS
Form 8.3 - PFIZER INC
  2:04 pm
RNS
Form 8.5 (EPT/RI) - replacement - Astrazeneca Plc
  2:03 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:01 pm
RNS
Form 8.5 (EPT/RI) - replacement - Astrazeneca Plc
  1:57 pm
RNS
Form 8.5 (EPT/RI) - replacement - Astrazeneca Plc
  1:37 pm
BUS
Form 8.3 - AstraZeneca plc
  1:15 pm
BUS
Form 8.3 - AstraZeneca PLC
  12:26 pm
RNS
Form 8.5 (EPT/NON-RI) Astrazenenca PLC
  12:06 pm
RNS
Form 8.5 (EPT/RI)
  11:58 am
RNS
Form 8.5 (EPT/RI)-AstraZeneca Plc
  11:55 am
RNS
Form 8.3 - AstraZeneca plc
  11:47 am
RNS
Form 8.5 (EPT/RI) Pfizer Plc
  11:44 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:08 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:01 am
RNS
Form 8.5 (EPT/RI) Pfizer Inc
  11:00 am
RNS
Rule 2.10 Announcement
  11:00 am
RNS
Total Voting Rights
  10:58 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:56 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:53 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  10:51 am
RNS
Rule 2.10 Announcement
  10:46 am
RNS
Form 8.5 (EPT/RI) Astrazeneca Plc
  7:00 am
RNS
Form 8.5 (EPT/NON-RI)
30 Apr 2014 4:45 pm
RNS
Form 8.3 - Astrazeneca/Pfizer
  4:05 pm
RNS
Form 8.5 (EPT/NON-RI)
  4:03 pm
RNS
Form 8.5 (EPT/RI)
  3:49 pm
RNS
Form 8.3 - Pfizer Inc
  3:44 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:42 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:34 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:29 pm
RNS
Form 8.3 - [AstraZeneca plc]
  3:29 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:28 pm
RNS
Form 8.3 - [AstraZeneca Plc]
  3:17 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:16 pm
RNS
Form 8.3 - PFIZER INC
  3:03 pm
RNS
Form 8.3 - [Pfizer Inc] Amendment
  2:59 pm
RNS
Form 8.5 (EPT/RI)replacement - Astrazeneca PLC
  2:57 pm
RNS
Form 8.3 - ASTRAZENECA PLC
  2:56 pm
RNS
Form 8.3 - [AstraZeneca Plc] Amendment
  2:24 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  2:24 pm
RNS
Form 8.3 - AstraZeneca PLC
  2:24 pm
BUS
Form 8.3 - Astrazeneca Plc
  2:11 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:09 pm
BUS
Form 8.3 - AstraZeneca PLC
  2:00 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:23 pm
RNS
Form 8.5 (EPT/NON-RI)
  12:26 pm
RNS
Form 8.5 (EPT/NON-RI) Astrazeneca PLC
  12:26 pm
RNS
Form 8.5 (EPT/NON-RI) Astrazeneca PLC
  12:06 pm
RNS
Form 8.5 (EPT/RI)
  11:55 am
RNS
Form 8.3 - Astrazeneca plc
  11:50 am
RNS
Form 8.5 (EPT/RI)
  11:50 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  11:49 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  11:48 am
RNS
Form 8.5 (EPT/RI) Astra Zeneca PLC
  11:46 am
RNS
Form 8.5 (EPT/RI)Astrazeneca PLC
  11:16 am
RNS
Rule 2.10 Announcement
  11:00 am
RNS
Rule 2.10 Announcement
  10:02 am
RNS
Form 8.3 - [Astrazeneca/Pfizer]Amend Supp form
  7:00 am
RNS
Form 8.5 (EPT/NON-RI)
  7:00 am
RNS
Form 8.5 (EPT/NON-RI)
  7:00 am
RNS
Form 8.5 (EPT/NON-RI)
  7:00 am
RNS
Form 8.5 (EPT/RI)
  7:00 am
RNS
Form 8.3- AstraZeneca Plc - Replacement
  7:00 am
RNS
Form 8.3 - AstraZeneca Plc
29 Apr 2014 5:54 pm
RNS
Form 8.3 - PFIZER INC
  5:43 pm
RNS
Form 8.3 - AstraZeneca PLC
  5:23 pm
RNS
Form 8.3 - [Astrazeneca/Pfizer]
  4:30 pm
RNS
Rule 2.10 Announcement
  4:01 pm
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  3:32 pm
BUS
Form 8.3 - AstraZeneca Plc
  3:28 pm
RNS
Form 8.3 - [Astrazeneca/Pfizer]
  3:27 pm
RNS
Form 8.3 - AstraZeneca Plc
  3:13 pm
RNS
Form 8.3 - [ASTRAZENECA PLC]
  3:05 pm
RNS
Form 8.3 - [AstraZeneca plc]
  2:58 pm
RNS
Form 8.3 - Pfizer Inc
  2:50 pm
RNS
Form 8.3 - AstraZeneca Plc
  2:46 pm
BUS
Form 8.3 - AstraZeneca PLC
  2:32 pm
RNS
Form 8.5 (EPT/RI)
  2:17 pm
RNS
Form 8.3 - [Astrazeneca Plc]
  1:52 pm
RNS
Form 8.3 - AstraZeneca Plc
  1:38 pm
BUS
Form 8.3 - Astrazeneca Plc
  12:30 pm
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  11:57 am
RNS
Form 8.5 (EPT/RI)-AstraZeneca Plc
  11:55 am
RNS
Form 8.3 - AstraZeneca plc
  11:49 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  11:47 am
RNS
Form 8.5 (EPT/RI) Astrazeneca PLC
  10:52 am
BUS
Form 8.3 - AstraZeneca PLC
  8:36 am
BUS
Form 8.3 - AstraZeneca PLC
  8:24 am
RNS
Rule 2.10 Announcement
  7:00 am
RNS
Form 8.5 (EPT/NON-RI)
  7:00 am
RNS
Form 8.5 (EPT/NON-RI)
28 Apr 2014 5:32 pm
RNS
Form 8.3 - Pfizer Inc
  5:31 pm
RNS
Form 8.3 - Replacement AstraZenica Plc
  5:02 pm
RNS
Form 8.3 - AstraZeneca PLC/Pfizer Inc 'Replacement
  2:28 pm
RNS
Form 8.3 - AstraZeneca Plc
  11:34 am
BUS
Form 8.3 - Astrazeneca Plc - Replacement
  10:41 am
BUS
Form 8.3 - Astrazeneca Plc
  10:35 am
RNS
Statement Regarding Pfizer Announcement
  7:00 am
RNS
Statement re Possible Offer
24 Apr 2014 5:20 pm
RNS
Result of AGM
  7:08 am
RNS
1st Quarter Results - Part 2
  7:08 am
RNS
1st Quarter Results
23 Apr 2014 9:00 am
RNS
Notice of Results
01 Apr 2014 2:00 pm
RNS
Director/PDMR Shareholding
  11:00 am
RNS
Total Voting Rights
31 Mar 2014 2:00 pm
RNS
Director/PDMR Shareholding
  2:00 pm
RNS
Director/PDMR Shareholding
  2:00 pm
RNS
Director/PDMR Shareholding
26 Mar 2014 11:00 am
RNS
Director/PDMR Shareholding
21 Mar 2014 7:00 am
RNS
Filing of Annual Report on Form 20-F with SEC
20 Mar 2014 11:00 am
RNS
Directorate Change
  11:00 am
RNS
Annual Financial Report
19 Mar 2014 3:00 pm
RNS
Director/PDMR Shareholding
12 Mar 2014 7:00 am
RNS
AstraZeneca announces sale of Alderley Park site
03 Mar 2014 4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
US FDA APPROVES BYDUREON? PEN
25 Feb 2014 6:24 pm
RNS
FDA Approves Orphan Drug Myalept
12 Feb 2014 3:30 pm
RNS
Director/PDMR Shareholding
11 Feb 2014 5:00 pm
RNS
Director/PDMR Shareholding
10 Feb 2014 5:30 pm
RNS
Director/PDMR Shareholding
07 Feb 2014 3:30 pm
RNS
Director/PDMR Shareholding
06 Feb 2014 7:00 am
RNS
Pipeline Table
  7:00 am
RNS
Final Results
05 Feb 2014 9:00 am
RNS
Notice of Results
03 Feb 2014 4:30 pm
RNS
Total Voting Rights
  7:00 am
RNS
AZ completes BMS diabetes acquisition
27 Jan 2014 10:30 am
RNS
Holding(s) in Company
22 Jan 2014 7:00 am
RNS
Xigduo approved in EU for type 2 diabetes
17 Jan 2014 10:42 am
RNS
Replacement re block listing application
14 Jan 2014 7:00 am
RNS
AstraZeneca provides strategy update at JP Morgan
13 Jan 2014 7:00 am
RNS
US FDA APPROVES FARXIGAT (DAPAGLIFLOZIN)
09 Jan 2014 7:00 am
RNS
US FDA Approval of Farxiga (dapagliflozin)
02 Jan 2014 4:00 pm
RNS
Total Voting Rights
27 Dec 2013 7:13 am
RNS
AZ and Shionogi extend Crestor agreement
19 Dec 2013 2:00 pm
RNS
Director/PDMR Shareholding
  7:50 am
RNS
AZ to acquire BMS share of diabetes assets
17 Dec 2013 6:13 pm
RNS
STATEMENT ON ESOMEPRAZOLE STRONTIUM LAUNCH IN US
13 Dec 2013 7:14 am
RNS
Top Line Results From Phase III Study of Lesinurad
  7:00 am
RNS
FDA Advisory Committee Recommends Dapagliflozin
12 Dec 2013 7:00 am
RNS
FDA Advisory Committee Votes on Metreleptin
06 Dec 2013 7:00 am
RNS
European Commission Approves Fluenz Tetra
02 Dec 2013 3:00 pm
RNS
Blocklisting Interim Review
  1:00 pm
RNS
Total Voting Rights
22 Nov 2013 1:42 pm
RNS
XIGDUO POSITIVE CHMP OPINION FOR TYPE 2 DIABETES
19 Nov 2013 7:00 am
RNS
NDA for Naloxegol accepted by US FDA
01 Nov 2013 4:00 pm
RNS
Total Voting Rights
  1:45 pm
RNS
Director/PDMR Shareholding
31 Oct 2013 7:02 am
RNS
US Court Decision in Pulmicort Respules Litigation
  7:01 am
RNS
Marc Dunoyer Appointed Chief Financial Officer
  7:00 am
RNS
3rd Quarter Results
30 Oct 2013 9:00 am
RNS
Notice of Results
  7:00 am
RNS
ASTRAZENECA ADVANCES BENRALIZUMAB TO PHASE III
22 Oct 2013 7:00 am
RNS
AstraZeneca starts phase III study for selumetinib
15 Oct 2013 7:00 am
RNS
Medimmune acquires Spirogen
07 Oct 2013 7:00 am
RNS
MedImmune completes Amplimmune acquisition
01 Oct 2013 4:00 pm
RNS
Total Voting Rights
30 Sep 2013 7:01 am
RNS
MAA FOR OLAPARIB ACCEPTED BY EMA
27 Sep 2013 7:00 am
RNS
MAA APPLICATION FOR NALOXEGOL ACCEPTED
20 Sep 2013 12:54 pm
RNS
Fluenz Tetra receives positive CHMP opinion in EU
04 Sep 2013 7:00 am
RNS
Starts phase III clinical programme for olaparib
02 Sep 2013 3:00 pm
RNS
Total Voting Rights
27 Aug 2013 7:00 am
RNS
MEDIMMUNE ACQUIRES AMPLIMMUNE
01 Aug 2013 4:00 pm
RNS
Total Voting Rights
  3:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Half Yearly Pipeline Update
  7:00 am
RNS
Half Yearly Report
31 Jul 2013 9:00 am
RNS
Notice of Results
  7:00 am
RNS
Collaborates with FibroGen on anaemia treatment
26 Jul 2013 7:00 am
RNS
FDA receipt of dapagliflozin resubmission
19 Jul 2013 7:00 am
RNS
AstraZeneca completes acquisition of Omthera
15 Jul 2013 7:00 am
RNS
Simon Lowth, CFO, to leave AstraZeneca
11 Jul 2013 4:30 pm
RNS
Holding(s) in Company
01 Jul 2013 3:00 pm
RNS
Total Voting Rights
28 Jun 2013 5:35 pm
RNS
Publication of Prospectus
  7:00 am
RNS
Completes Acquisition of Pearl Therapeutics
19 Jun 2013 7:00 am
RNS
Announces top-line results for SAVOR study
12 Jun 2013 3:00 pm
RNS
Director/PDMR Shareholding
  3:00 pm
RNS
Director/PDMR Shareholding
  3:00 pm
RNS
Director/PDMR Shareholding
10 Jun 2013 7:00 am
RNS
To Acquire Pearl Therapeutics
04 Jun 2013 7:00 am
RNS
Top-line results from Phase III Oskira trials
03 Jun 2013 1:00 pm
RNS
Blocklisting Interim Review
  12:00 pm
RNS
Total Voting Rights
28 May 2013 7:00 am
RNS
Appeal against generic PULMICORT RESPULES
  7:00 am
RNS
Acquires Omthera Pharmaceuticals
14 May 2013 2:00 pm
RNS
Director/PDMR Shareholding
08 May 2013 2:00 pm
RNS
Director/PDMR Shareholding
  2:00 pm
RNS
Director/PDMR Shareholding
02 May 2013 1:00 pm
RNS
Director/PDMR Shareholding
01 May 2013 3:00 pm
RNS
Director/PDMR Shareholding
  2:00 pm
RNS
Total Voting Rights
29 Apr 2013 3:00 pm
RNS
Director/PDMR Shareholding
  3:00 pm
RNS
Director/PDMR Shareholding
25 Apr 2013 5:50 pm
RNS
Result of AGM
  7:00 am
RNS
1st Quarter Results
24 Apr 2013 9:00 am
RNS
Notice of Results
05 Apr 2013 7:00 am
RNS
Top-line results from OSKIRA-1 phase III study
03 Apr 2013 4:00 pm
RNS
Director/PDMR Shareholding
  4:00 pm
RNS
Director/PDMR Shareholding
02 Apr 2013 4:00 pm
RNS
Total Voting Rights
  2:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
US court says one PULMICORT patent invalid
27 Mar 2013 2:30 pm
RNS
Director/PDMR Shareholding
  2:30 pm
RNS
Director/PDMR Shareholding
26 Mar 2013 3:13 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Filing of Annual Report on Form 20-F with SEC
25 Mar 2013 11:38 am
RNS
Annual Financial Report
  7:00 am
RNS
AstraZeneca settles over Crestor patent
21 Mar 2013 7:00 am
RNS
AstraZeneca announces agreement with Moderna
  7:00 am
RNS
AstraZeneca partners Karolinska Institute
  7:00 am
RNS
AstraZeneca outlines growth strategy
18 Mar 2013 1:00 pm
RNS
AstraZeneca to establish strategic R&D centres
14 Mar 2013 10:00 am
RNS
Block Listing Application
05 Mar 2013 7:00 am
RNS
Australian court holds crestor patents invalid
01 Mar 2013 4:00 pm
RNS
Total Voting Rights
27 Feb 2013 10:00 am
RNS
Director/PDMR Shareholding
  10:00 am
RNS
Director/PDMR Shareholding
  10:00 am
RNS
Director/PDMR Shareholding
  10:00 am
RNS
Director/PDMR Shareholding
01 Feb 2013 4:00 pm
RNS
Total Voting Rights
31 Jan 2013 7:00 am
RNS
Final Results
  7:00 am
RNS
Final Results
30 Jan 2013 9:00 am
RNS
Notice of Results
15 Jan 2013 1:00 pm
RNS
Announces changes to Senior Executive Team
02 Jan 2013 4:00 pm
RNS
Total Voting Rights
28 Dec 2012 3:58 pm
RNS
Director/PDMR Shareholding
14 Dec 2012 5:56 pm
RNS
CRESTOR US Patent Upheld
13 Dec 2012 2:59 pm
RNS
Top-line results of OSKIRA-4
07 Dec 2012 2:30 pm
RNS
Director/PDMR Shareholding
06 Dec 2012 2:30 pm
RNS
Director/PDMR Shareholding
03 Dec 2012 3:00 pm
RNS
Blocklisting Interim Review
  3:00 pm
RNS
Total Voting Rights
22 Nov 2012 2:30 pm
RNS
Director/PDMR Shareholding
21 Nov 2012 2:30 pm
RNS
Director/PDMR Shareholding
15 Nov 2012 4:30 pm
RNS
Director/PDMR Shareholding
14 Nov 2012 4:49 pm
RNS
FORXIGA first in class SGLT2 gets EU approval
12 Nov 2012 4:30 pm
RNS
Definition of Core Financial Measures
  7:00 am
RNS
Top-line phase III results for Naloxegol
01 Nov 2012 3:00 pm
RNS
Total Voting Rights
29 Oct 2012 1:10 pm
RNS
Director/PDMR Shareholding
  1:10 pm
RNS
Director/PDMR Shareholding
25 Oct 2012 7:00 am
RNS
3rd Quarter Results
24 Oct 2012 9:00 am
RNS
Notice of Results
01 Oct 2012 4:30 pm
RNS
Total Voting Rights
  2:00 pm
RNS
AstraZeneca suspends share repurchase programme
26 Sep 2012 7:00 am
RNS
Transaction in Own Shares
25 Sep 2012 7:00 am
RNS
Transaction in Own Shares
19 Sep 2012 8:48 am
RNS
Transaction in Own Shares
18 Sep 2012 7:00 am
RNS
Transaction in Own Shares
17 Sep 2012 7:00 am
RNS
Transaction in Own Shares
14 Sep 2012 7:00 am
RNS
Transaction in Own Shares
12 Sep 2012 7:00 am
RNS
AstraZeneca prices a $2 billion bond issue
11 Sep 2012 7:00 am
RNS
Transaction in Own Shares
10 Sep 2012 7:00 am
RNS
Transaction in Own Shares
07 Sep 2012 7:00 am
RNS
Transaction in Own Shares
06 Sep 2012 7:00 am
RNS
Transaction in Own Shares
05 Sep 2012 7:00 am
RNS
Transaction in Own Shares
04 Sep 2012 7:00 am
RNS
Transaction in Own Shares
03 Sep 2012 4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Transaction in Own Shares
31 Aug 2012 5:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
30 Aug 2012 5:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
29 Aug 2012 7:00 am
RNS
Transaction in Own Shares
28 Aug 2012 7:00 am
RNS
European Commission approves Zinforo
  7:00 am
RNS
Pascal Soriot appointed CEO
  7:00 am
RNS
Transaction in Own Shares
24 Aug 2012 4:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
23 Aug 2012 7:00 am
RNS
Transaction in Own Shares
22 Aug 2012 7:00 am
RNS
Transaction in Own Shares
21 Aug 2012 7:00 am
RNS
Transaction in Own Shares
20 Aug 2012 7:00 am
RNS
Transaction in Own Shares
17 Aug 2012 7:00 am
RNS
Transaction in Own Shares
15 Aug 2012 7:00 am
RNS
Transaction in Own Shares
14 Aug 2012 7:00 am
RNS
Partners Pfizer for over-the-counter Nexium
09 Aug 2012 12:45 pm
RNS
Bristol-Myers Squibb completes purchase of Amylin
06 Aug 2012 7:00 am
RNS
Transaction in Own Shares
03 Aug 2012 7:00 am
RNS
Transaction in Own Shares
02 Aug 2012 7:00 am
RNS
Transaction in Own Shares
01 Aug 2012 4:00 pm
RNS
Total Voting Rights
  2:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
31 Jul 2012 7:00 am
RNS
Transaction in Own Shares
30 Jul 2012 7:00 am
RNS
Transaction in Own Shares
27 Jul 2012 7:00 am
RNS
Transaction in Own Shares
26 Jul 2012 7:05 am
RNS
Transaction in Own Shares
  7:00 am
RNS
Pipeline table: Second Quarter & Half Year(2 of 2)
  7:00 am
RNS
Second Quarter & Half Year Results (1 of 2)
25 Jul 2012 9:00 am
RNS
Notice of Results
  7:00 am
RNS
Transaction in Own Shares
24 Jul 2012 7:00 am
RNS
Transaction in Own Shares
23 Jul 2012 7:00 am
RNS
Transaction in Own Shares
20 Jul 2012 7:00 am
RNS
Transaction in Own Shares
19 Jul 2012 7:00 am
RNS
Transaction in Own Shares
18 Jul 2012 7:00 am
RNS
Transaction in Own Shares
17 Jul 2012 7:00 am
RNS
Transaction in Own Shares
16 Jul 2012 7:00 am
RNS
Transaction in Own Shares
13 Jul 2012 7:00 am
RNS
Transaction in Own Shares
12 Jul 2012 7:00 am
RNS
Transaction in Own Shares
11 Jul 2012 7:00 am
RNS
Transaction in Own Shares
10 Jul 2012 7:00 am
RNS
Transaction in Own Shares
06 Jul 2012 7:00 am
RNS
Transaction in Own Shares
05 Jul 2012 7:00 am
RNS
Transaction in Own Shares
04 Jul 2012 7:00 am
RNS
Transaction in Own Shares
03 Jul 2012 7:00 am
RNS
Transaction in Own Shares
02 Jul 2012 4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
AZ expands alliance with BMS through Amlyn
  7:00 am
RNS
Transaction in Own Shares
29 Jun 2012 2:45 pm
RNS
Publication of Prospectus
  7:00 am
RNS
Transaction in Own Shares
28 Jun 2012 7:00 am
RNS
Transaction in Own Shares
27 Jun 2012 12:01 pm
RNS
AstraZeneca and Merck agree to amend second option
  7:00 am
RNS
Transaction in Own Shares
26 Jun 2012 7:00 am
RNS
Transaction in Own Shares
25 Jun 2012 7:00 am
RNS
Transaction in Own Shares
22 Jun 2012 12:24 pm
RNS
Zinforo receives positive CHMP opinion in the EU
  9:00 am
RNS
Share Repurchase Programme
  7:00 am
RNS
Transaction in Own Shares
21 Jun 2012 7:00 am
RNS
Transaction in Own Shares
20 Jun 2012 7:00 am
RNS
AstraZeneca completes acquisition of Ardea
19 Jun 2012 7:00 am
RNS
Transaction in Own Shares
18 Jun 2012 7:00 am
RNS
Transaction in Own Shares
15 Jun 2012 7:00 am
RNS
Transaction in Own Shares
14 Jun 2012 7:00 am
RNS
Transaction in Own Shares
08 Jun 2012 7:00 am
RNS
Transaction in Own Shares
07 Jun 2012 7:00 am
RNS
Transaction in Own Shares
06 Jun 2012 7:00 am
RNS
Transaction in Own Shares
01 Jun 2012 4:30 pm
RNS
Blocklisting Interim Review
  4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Transaction in Own Shares
31 May 2012 4:30 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
30 May 2012 7:00 am
RNS
Transaction in Own Shares
28 May 2012 7:00 am
RNS
Transaction in Own Shares
25 May 2012 7:00 am
RNS
Transaction in Own Shares
24 May 2012 7:00 am
RNS
Transaction in Own Shares
21 May 2012 7:00 am
RNS
Transaction in Own Shares
18 May 2012 7:00 am
RNS
Transaction in Own Shares
17 May 2012 7:00 am
RNS
Transaction in Own Shares
16 May 2012 7:00 am
RNS
Transaction in Own Shares
15 May 2012 7:00 am
RNS
Transaction in Own Shares
14 May 2012 7:00 am
RNS
Transaction in Own Shares
11 May 2012 7:00 am
RNS
Transaction in Own Shares
10 May 2012 7:00 am
RNS
Transaction in Own Shares
09 May 2012 7:00 am
RNS
Transaction in Own Shares
08 May 2012 7:00 am
RNS
Transaction in Own Shares
04 May 2012 7:00 am
RNS
Transaction in Own Shares
03 May 2012 7:00 am
RNS
Transaction in Own Shares
02 May 2012 7:00 am
RNS
Transaction in Own Shares
01 May 2012 4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Transaction in Own Shares
30 Apr 2012 7:00 am
RNS
Transaction in Own Shares
27 Apr 2012 4:30 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
26 Apr 2012 6:09 pm
RNS
Result of AGM
  7:05 am
RNS
Transaction in Own Shares
  7:03 am
RNS
David Brennan to retire as CEO 1 June 2012
  7:00 am
RNS
1st Quarter Results
25 Apr 2012 9:00 am
RNS
Notice of Results
  7:00 am
RNS
Transaction in Own Shares
24 Apr 2012 7:00 am
RNS
Transaction in Own Shares
23 Apr 2012 7:00 am
RNS
Acquires Ardea Biosciences for $1 billion
  7:00 am
RNS
Transaction in Own Shares
20 Apr 2012 2:17 pm
RNS
FORXIGA gets positive CHMP opinion in the EU
  7:00 am
RNS
Transaction in Own Shares
19 Apr 2012 7:00 am
RNS
Transaction in Own Shares
18 Apr 2012 7:00 am
RNS
Transaction in Own Shares
17 Apr 2012 7:00 am
RNS
Transaction in Own Shares
16 Apr 2012 7:00 am
RNS
Transaction in Own Shares
13 Apr 2012 7:00 am
RNS
Transaction in Own Shares
12 Apr 2012 7:00 am
RNS
Transaction in Own Shares
11 Apr 2012 4:30 pm
RNS
Annual Information Update
  7:00 am
RNS
Transaction in Own Shares
10 Apr 2012 7:00 am
RNS
Transaction in Own Shares
05 Apr 2012 7:00 am
RNS
Transaction in Own Shares
04 Apr 2012 7:00 am
RNS
Transaction in Own Shares
03 Apr 2012 7:00 am
RNS
Partners Amgen to develop inflammation portfolio
  7:00 am
RNS
Transaction in Own Shares
02 Apr 2012 4:00 pm
RNS
Director/PDMR Shareholding
  4:00 pm
RNS
Director/PDMR Shareholding
  4:00 pm
RNS
Director/PDMR Shareholding
  4:00 pm
RNS
Director/PDMR Shareholding
  3:30 pm
RNS
Total Voting Rights
  7:00 am
RNS
Transaction in Own Shares
30 Mar 2012 4:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
  7:00 am
RNS
US Court Finds Seroquel XR Patent Valid
29 Mar 2012 5:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Filing of Annual Report on Form 20-F with SEC
  7:00 am
RNS
Transaction in Own Shares
28 Mar 2012 5:00 pm
RNS
Director/PDMR Shareholding
  5:00 pm
RNS
Director/PDMR Shareholding
  5:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
27 Mar 2012 7:00 am
RNS
Transaction in Own Shares
26 Mar 2012 11:40 am
RNS
Annual Financial Report
  7:00 am
RNS
Transaction in Own Shares
  7:00 am
RNS
US Court dismisses lawsuit against the FDA
23 Mar 2012 7:00 am
RNS
Transaction in Own Shares
22 Mar 2012 10:25 am
RNS
UK Court finds Seroquel XR patent invalid
  7:00 am
RNS
Transaction in Own Shares
21 Mar 2012 7:00 am
RNS
Transaction in Own Shares
20 Mar 2012 7:00 am
RNS
TC-5214 Phase III studies do not meet endpoint
  7:00 am
RNS
Transaction in Own Shares
19 Mar 2012 7:00 am
RNS
Transaction in Own Shares
16 Mar 2012 7:00 am
RNS
Transaction in Own Shares
15 Mar 2012 7:00 am
RNS
Transaction in Own Shares
14 Mar 2012 7:00 am
RNS
Transaction in Own Shares
13 Mar 2012 7:00 am
RNS
Files lawsuit against FDA decision on quetiapine
  7:00 am
RNS
Transaction in Own Shares
12 Mar 2012 7:00 am
RNS
Transaction in Own Shares
09 Mar 2012 7:00 am
RNS
Transaction in Own Shares
08 Mar 2012 7:00 am
RNS
Transaction in Own Shares
07 Mar 2012 7:00 am
RNS
Transaction in Own Shares
06 Mar 2012 7:00 am
RNS
Transaction in Own Shares
02 Mar 2012 2:00 pm
RNS
Share Repurchase Programme
  7:00 am
RNS
Transaction in Own Shares
01 Mar 2012 4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Announces Non-Executive and Chairman changes
29 Feb 2012 7:00 am
RNS
Transaction in Own Shares
28 Feb 2012 5:30 pm
RNS
Director/PDMR Shareholding
  5:30 pm
RNS
Director/PDMR Shareholding
  5:30 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
27 Feb 2012 5:30 pm
RNS
Director/PDMR Shareholding
  5:30 pm
RNS
Director/PDMR Shareholding
  5:30 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
24 Feb 2012 7:00 am
RNS
Transaction in Own Shares
23 Feb 2012 7:00 am
RNS
Transaction in Own Shares
22 Feb 2012 7:00 am
RNS
Transaction in Own Shares
21 Feb 2012 8:00 am
RNS
EU approves Caprelsa for thyroid cancer
  7:00 am
RNS
Transaction in Own Shares
20 Feb 2012 7:00 am
RNS
Transaction in Own Shares
17 Feb 2012 7:00 am
RNS
Transaction in Own Shares
16 Feb 2012 7:00 am
RNS
Director Declaration
  7:00 am
RNS
Transaction in Own Shares
15 Feb 2012 7:00 am
RNS
Transaction in Own Shares
14 Feb 2012 7:00 am
RNS
Transaction in Own Shares
13 Feb 2012 7:00 am
RNS
Transaction in Own Shares
10 Feb 2012 7:00 am
RNS
Transaction in Own Shares
09 Feb 2012 7:00 am
RNS
Transaction in Own Shares
08 Feb 2012 7:00 am
RNS
Transaction in Own Shares
07 Feb 2012 7:00 am
RNS
Transaction in Own Shares
06 Feb 2012 7:00 am
RNS
Transaction in Own Shares
03 Feb 2012 4:30 pm
RNS
Holding(s) in Company
  3:30 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
02 Feb 2012 1:00 pm
RNS
Share Repurchase Programme
  7:05 am
RNS
Transaction in Own Shares
  7:01 am
RNS
Final Results - Part 3 of 3
  7:00 am
RNS
Final Results - Part 2 of 3
  7:00 am
RNS
Final Results - Part 1 of 3
01 Feb 2012 4:00 pm
RNS
Total Voting Rights
  9:00 am
RNS
Notice of Results
  7:00 am
RNS
Transaction in Own Shares
31 Jan 2012 7:00 am
RNS
Transaction in Own Shares
30 Jan 2012 7:00 am
RNS
Transaction in Own Shares
27 Jan 2012 7:00 am
RNS
Transaction in Own Shares
26 Jan 2012 7:00 am
RNS
Transaction in Own Shares
25 Jan 2012 7:00 am
RNS
Transaction in Own Shares
24 Jan 2012 7:00 am
RNS
Transaction in Own Shares
23 Jan 2012 7:01 am
RNS
Transaction in Own Shares
20 Jan 2012 7:00 am
RNS
Transaction in Own Shares
19 Jan 2012 7:00 am
RNS
Transaction in Own Shares
  7:00 am
RNS
FDA COMPLETE RESPONSE LETTER FOR DAPAGLIFLOZIN
18 Jan 2012 7:00 am
RNS
Transaction in Own Shares
16 Jan 2012 7:00 am
RNS
Transaction in Own Shares
13 Jan 2012 7:00 am
RNS
Transaction in Own Shares
12 Jan 2012 7:00 am
RNS
Transaction in Own Shares
11 Jan 2012 7:00 am
RNS
Transaction in Own Shares
10 Jan 2012 7:00 am
RNS
Transaction in Own Shares
09 Jan 2012 7:00 am
RNS
Reaffirms financial guidance for 2011
  7:00 am
RNS
Transaction in Own Shares
06 Jan 2012 7:00 am
RNS
Transaction in Own Shares
05 Jan 2012 7:00 am
RNS
Transaction in Own Shares
04 Jan 2012 11:03 am
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
03 Jan 2012 4:00 pm
RNS
Total Voting Rights
29 Dec 2011 7:00 am
RNS
Transaction in Own Shares
23 Dec 2011 7:00 am
RNS
Transaction in Own Shares
22 Dec 2011 7:00 am
RNS
Transaction in Own Shares
21 Dec 2011 7:00 am
RNS
Transaction in Own Shares
20 Dec 2011 7:00 am
RNS
UPDATES ON OLAPARIB AND TC-5214 PROGRAMMES
  7:00 am
RNS
Transaction in Own Shares
19 Dec 2011 7:00 am
RNS
Transaction in Own Shares
16 Dec 2011 1:14 pm
RNS
Transaction in Own Shares
15 Dec 2011 4:30 pm
RNS
Share Repurchase Programme
  7:00 am
RNS
Transaction in Own Shares
14 Dec 2011 7:00 am
RNS
Transaction in Own Shares
13 Dec 2011 7:00 am
RNS
Transaction in Own Shares
12 Dec 2011 7:00 am
RNS
Transaction in Own Shares
09 Dec 2011 7:00 am
RNS
Transaction in Own Shares
08 Dec 2011 7:00 am
RNS
AstraZeneca streamlines US sales organisation
  7:00 am
RNS
Transaction in Own Shares
07 Dec 2011 7:00 am
RNS
Transaction in Own Shares
06 Dec 2011 7:00 am
RNS
Transaction in Own Shares
05 Dec 2011 7:00 am
RNS
Transaction in Own Shares
02 Dec 2011 7:00 am
RNS
Transaction in Own Shares
01 Dec 2011 4:30 pm
RNS
Blocklisting Interim Review
  4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Transaction in Own Shares
30 Nov 2011 7:00 am
RNS
Transaction in Own Shares
29 Nov 2011 7:00 am
RNS
Komboglyze gets EU marketing authorisation
  7:00 am
RNS
Transaction in Own Shares
28 Nov 2011 7:00 am
RNS
Transaction in Own Shares
25 Nov 2011 7:00 am
RNS
Transaction in Own Shares
24 Nov 2011 7:00 am
RNS
Transaction in Own Shares
23 Nov 2011 7:00 am
RNS
Transaction in Own Shares
22 Nov 2011 7:00 am
RNS
Transaction in Own Shares
21 Nov 2011 7:00 am
RNS
Transaction in Own Shares
18 Nov 2011 7:00 am
RNS
Transaction in Own Shares
17 Nov 2011 7:00 am
RNS
Transaction in Own Shares
16 Nov 2011 7:00 am
RNS
Transaction in Own Shares
15 Nov 2011 7:00 am
RNS
Transaction in Own Shares
14 Nov 2011 7:00 am
RNS
Transaction in Own Shares
11 Nov 2011 7:00 am
RNS
Transaction in Own Shares
10 Nov 2011 7:00 am
RNS
Transaction in Own Shares
09 Nov 2011 7:00 am
RNS
Transaction in Own Shares
08 Nov 2011 7:00 am
RNS
First top line results for TC-5214 with Targacept
  7:00 am
RNS
Transaction in Own Shares
07 Nov 2011 7:00 am
RNS
Transaction in Own Shares
04 Nov 2011 7:00 am
RNS
Transaction in Own Shares
03 Nov 2011 7:00 am
RNS
Transaction in Own Shares
02 Nov 2011 7:00 am
RNS
Transaction in Own Shares
01 Nov 2011 4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Transaction in Own Shares
31 Oct 2011 7:00 am
RNS
Transaction in Own Shares
28 Oct 2011 3:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
27 Oct 2011 7:05 am
RNS
FDA extends dapa action date by three months
  7:00 am
RNS
3rd Quarter Results - Part 2 of 2
  7:00 am
RNS
3rd Quarter Results - Part 1 of 2
  7:00 am
RNS
Transaction in Own Shares
26 Oct 2011 9:00 am
RNS
Notice of Results
  7:00 am
RNS
Transaction in Own Shares
25 Oct 2011 7:00 am
RNS
Transaction in Own Shares
24 Oct 2011 7:00 am
RNS
Transaction in Own Shares
21 Oct 2011 7:00 am
RNS
Transaction in Own Shares
20 Oct 2011 7:00 am
RNS
Transaction in Own Shares
19 Oct 2011 7:00 am
RNS
Transaction in Own Shares
18 Oct 2011 7:00 am
RNS
Transaction in Own Shares
17 Oct 2011 7:00 am
RNS
Transaction in Own Shares
14 Oct 2011 7:00 am
RNS
Transaction in Own Shares
13 Oct 2011 7:00 am
RNS
Transaction in Own Shares
12 Oct 2011 7:00 am
RNS
Transaction in Own Shares
11 Oct 2011 7:00 am
RNS
Transaction in Own Shares
10 Oct 2011 7:00 am
RNS
Transaction in Own Shares
07 Oct 2011 7:00 am
RNS
Transaction in Own Shares
06 Oct 2011 7:00 am
RNS
Transaction in Own Shares
05 Oct 2011 1:30 pm
RNS
Settles with Accord and Intas over Seroquel XR
  7:00 am
RNS
Transaction in Own Shares
04 Oct 2011 7:00 am
RNS
Transaction in Own Shares
03 Oct 2011 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Transaction in Own Shares
30 Sep 2011 2:00 pm
RNS
Share Repurchase Programme
  7:00 am
RNS
US Seroquel XR Patent Litigation
  7:00 am
RNS
Transaction in Own Shares
29 Sep 2011 7:00 am
RNS
Transaction in Own Shares
28 Sep 2011 7:00 am
RNS
Transaction in Own Shares
27 Sep 2011 7:00 am
RNS
Transaction in Own Shares
26 Sep 2011 7:00 am
RNS
Transaction in Own Shares
23 Sep 2011 1:22 pm
RNS
Komboglyze receives positive CHMP opinion
  7:00 am
RNS
Transaction in Own Shares
22 Sep 2011 7:00 am
RNS
Transaction in Own Shares
21 Sep 2011 7:00 am
RNS
Transaction in Own Shares
20 Sep 2011 7:00 am
RNS
Transaction in Own Shares
19 Sep 2011 7:00 am
RNS
Transaction in Own Shares
16 Sep 2011 7:00 am
RNS
Transaction in Own Shares
15 Sep 2011 7:00 am
RNS
Transaction in Own Shares
14 Sep 2011 7:00 am
RNS
Transaction in Own Shares
13 Sep 2011 8:30 am
RNS
Blocklisting Interim Review
  8:30 am
RNS
Block Listing Application
  7:00 am
RNS
Transaction in Own Shares
12 Sep 2011 7:00 am
RNS
Transaction in Own Shares
09 Sep 2011 7:00 am
RNS
Transaction in Own Shares
08 Sep 2011 7:00 am
RNS
Transaction in Own Shares
07 Sep 2011 7:00 am
RNS
Transaction in Own Shares
06 Sep 2011 7:00 am
RNS
Transaction in Own Shares
05 Sep 2011 7:00 am
RNS
Transaction in Own Shares
02 Sep 2011 7:00 am
RNS
Top-Line Results from SATURN study
  7:00 am
RNS
Transaction in Own Shares
01 Sep 2011 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Transaction in Own Shares
31 Aug 2011 5:30 pm
RNS
Director/PDMR Shareholding
  3:40 pm
RNS
Sale of AstraTech to DENTSPLY complete
  7:00 am
RNS
Transaction in Own Shares
30 Aug 2011 5:30 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
26 Aug 2011 4:00 pm
RNS
Share Repurchase Programme
  7:00 am
RNS
Transaction in Own Shares
25 Aug 2011 7:00 am
RNS
Transaction in Own Shares
24 Aug 2011 8:30 am
RNS
Block Listing Application
  7:00 am
RNS
Transaction in Own Shares
23 Aug 2011 7:00 am
RNS
Transaction in Own Shares
22 Aug 2011 7:00 am
RNS
Transaction in Own Shares
19 Aug 2011 7:00 am
RNS
Transaction in Own Shares
18 Aug 2011 7:00 am
RNS
Transaction in Own Shares
17 Aug 2011 7:00 am
RNS
Transaction in Own Shares
15 Aug 2011 7:00 am
RNS
Transaction in Own Shares
12 Aug 2011 4:30 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
11 Aug 2011 7:00 am
RNS
Transaction in Own Shares
10 Aug 2011 4:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
09 Aug 2011 7:00 am
RNS
Transaction in Own Shares
08 Aug 2011 7:00 am
RNS
Transaction in Own Shares
05 Aug 2011 7:00 am
RNS
Transaction in Own Shares
04 Aug 2011 7:00 am
RNS
Transaction in Own Shares
03 Aug 2011 7:00 am
RNS
Transaction in Own Shares
02 Aug 2011 7:00 am
RNS
Transaction in Own Shares
01 Aug 2011 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Transaction in Own Shares
29 Jul 2011 7:00 am
RNS
Transaction in Own Shares
28 Jul 2011 7:00 am
RNS
Second Quarter Results 2011 - Part 3 of 3
  7:00 am
RNS
Second Quarter Results 2011 - Part 2 of 3
  7:00 am
RNS
Second Quarter Results 2011 - Part 1 of 3
  7:00 am
RNS
Transaction in Own Shares
27 Jul 2011 9:00 am
RNS
Notice of Results
  7:00 am
RNS
Transaction in Own Shares
26 Jul 2011 7:00 am
RNS
Transaction in Own Shares
25 Jul 2011 7:00 am
RNS
Transaction in Own Shares
22 Jul 2011 7:00 am
RNS
Transaction in Own Shares
21 Jul 2011 7:00 am
RNS
FDA approves Brilinta for use in the US
  7:00 am
RNS
Transaction in Own Shares
20 Jul 2011 7:00 am
RNS
FDA advisors make recommendation on dapagliflozin
  7:00 am
RNS
Transaction in Own Shares
19 Jul 2011 7:00 am
RNS
Transaction in Own Shares
18 Jul 2011 7:00 am
RNS
Transaction in Own Shares
15 Jul 2011 7:00 am
RNS
Transaction in Own Shares
14 Jul 2011 7:00 am
RNS
Transaction in Own Shares
13 Jul 2011 7:00 am
RNS
Transaction in Own Shares
12 Jul 2011 7:00 am
RNS
Transaction in Own Shares
11 Jul 2011 7:00 am
RNS
Transaction in Own Shares
08 Jul 2011 7:00 am
RNS
Transaction in Own Shares
07 Jul 2011 7:00 am
RNS
Transaction in Own Shares
06 Jul 2011 7:00 am
RNS
Transaction in Own Shares
05 Jul 2011 7:00 am
RNS
Transaction in Own Shares
04 Jul 2011 7:00 am
RNS
Transaction in Own Shares
01 Jul 2011 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Nexium gets first approval in Japan
  7:00 am
RNS
Transaction in Own Shares
30 Jun 2011 7:00 am
RNS
Transaction in Own Shares
29 Jun 2011 7:00 am
RNS
Transaction in Own Shares
28 Jun 2011 7:00 am
RNS
Transaction in Own Shares
27 Jun 2011 7:00 am
RNS
Announces Phase3 study with BMS on Dapagliflozin
  7:00 am
RNS
Transaction in Own Shares
24 Jun 2011 7:00 am
RNS
Transaction in Own Shares
23 Jun 2011 7:00 am
RNS
Transaction in Own Shares
22 Jun 2011 7:00 am
RNS
Sells Astra Tech to Dentsply International
  7:00 am
RNS
Transaction in Own Shares
21 Jun 2011 7:00 am
RNS
Transaction in Own Shares
20 Jun 2011 7:00 am
RNS
Transaction in Own Shares
17 Jun 2011 7:00 am
RNS
Transaction in Own Shares
16 Jun 2011 7:00 am
RNS
Transaction in Own Shares
15 Jun 2011 4:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Transaction in Own Shares
14 Jun 2011 7:00 am
RNS
Transaction in Own Shares
13 Jun 2011 7:00 am
RNS
Transaction in Own Shares
10 Jun 2011 7:00 am
RNS
Transaction in Own Shares
08 Jun 2011 7:00 am
RNS
Transaction in Own Shares
07 Jun 2011 7:00 am
RNS
Transaction in Own Shares
06 Jun 2011 7:00 am
RNS
Transaction in Own Shares
03 Jun 2011 7:00 am
RNS
Transaction in Own Shares
02 Jun 2011 7:00 am
RNS
Transaction in Own Shares
01 Jun 2011 4:30 pm
RNS
Total Voting Rights
  7:00 am
RNS
Health Canada approves Brilinta
  7:00 am
RNS
Transaction in Own Shares
31 May 2011 7:00 am
RNS
Transaction in Own Shares
26 May 2011 7:00 am
RNS
Transaction in Own Shares
25 May 2011 7:00 am
RNS
Transaction in Own Shares
24 May 2011 4:00 pm
RNS
Director/PDMR Shareholding
23 May 2011 7:00 am
RNS
Transaction in Own Shares
20 May 2011 7:00 am
RNS
Transaction in Own Shares
19 May 2011 7:00 am
RNS
Transaction in Own Shares
18 May 2011 7:00 am
RNS
Transaction in Own Shares
17 May 2011 7:00 am
RNS
Transaction in Own Shares
16 May 2011 7:00 am
RNS
Transaction in Own Shares
13 May 2011 7:00 am
RNS
Transaction in Own Shares
12 May 2011 7:00 am
RNS
Transaction in Own Shares
11 May 2011 7:00 am
RNS
Transaction in Own Shares
10 May 2011 7:00 am
RNS
Transaction in Own Shares
06 May 2011 4:00 pm
RNS